BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011;3:99ra86. [PMID: 21900593 DOI: 10.1126/scitranslmed.3002442] [Cited by in Crossref: 382] [Cited by in F6Publishing: 370] [Article Influence: 38.2] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Kang Z, Lv D, Zhang X, Liao Y, Li Y, Liu R, Li P, Tong M, Tian J, Shao Y, Huang C, Ge D, Zhang J, Bai W, Wang Y, Liu Q, Li Z, Yan J. Longitudinal whole-genome sequencing reveals the evolution of MPAL. Cancer Genetics 2020;240:59-65. [DOI: 10.1016/j.cancergen.2019.11.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Campbell NP, Hensing TA, Bhayani MK, Shaikh AY, Brockstein BE. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther 2016;16:847-58. [PMID: 27400139 DOI: 10.1080/14737140.2016.1202116] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
3 Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, Hobor S, Jacobs B, Ercolani C, Lamba S, Scala E, Veronese S, Laurent-Puig P, Siena S, Tejpar S, Mottolese M, Punt CJ, Gambacorta M, Bardelli A, Di Nicolantonio F. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer 2013;133:1259-65. [PMID: 23404247 DOI: 10.1002/ijc.28106] [Cited by in Crossref: 122] [Cited by in F6Publishing: 110] [Article Influence: 13.6] [Reference Citation Analysis]
4 Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken J, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'hoore A, Diaz-rubio E, Douillard J, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne C, Labianca R, Laurent-puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen W, Papamichael D, Pentheroudakis G, Pfeiffer P, Price T, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll H, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology 2016;27:1386-422. [DOI: 10.1093/annonc/mdw235] [Cited by in Crossref: 1387] [Cited by in F6Publishing: 1250] [Article Influence: 231.2] [Reference Citation Analysis]
5 Pellino G, Gallo G, Pallante P, Capasso R, De Stefano A, Maretto I, Malapelle U, Qiu S, Nikolaou S, Barina A, Clerico G, Reginelli A, Giuliani A, Sciaudone G, Kontovounisios C, Brunese L, Trompetto M, Selvaggi F. Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. Gastroenterol Res Pract. 2018;2018:2397863. [PMID: 30008744 DOI: 10.1155/2018/2397863] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
6 Gracia-cazaña T, Salazar N, Zamarrón A, Mascaraque M, Lucena S, Juarranz Á. Resistance of Nonmelanoma Skin Cancer to Nonsurgical Treatments. Part II: Photodynamic Therapy, Vismodegib, Cetuximab, Intralesional Methotrexate, and Radiotherapy. Actas Dermo-Sifiliográficas (English Edition) 2016;107:740-50. [DOI: 10.1016/j.adengl.2016.08.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Schumacher D, Andrieux G, Boehnke K, Keil M, Silvestri A, Silvestrov M, Keilholz U, Haybaeck J, Erdmann G, Sachse C, Templin M, Hoffmann J, Boerries M, Schäfer R, Regenbrecht CRA. Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures. PLoS Genet 2019;15:e1008076. [PMID: 30925167 DOI: 10.1371/journal.pgen.1008076] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
8 Redmond KL, Papafili A, Lawler M, Van Schaeybroeck S. Overcoming Resistance to Targeted Therapies in Cancer. Semin Oncol. 2015;42:896-908. [PMID: 26615134 DOI: 10.1053/j.seminoncol.2015.09.028] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
9 Chen J, Zhang N, Wen J, Zhang Z. Silencing TAK1 alters gene expression signatures in bladder cancer cells. Oncol Lett 2017;13:2975-81. [PMID: 28521404 DOI: 10.3892/ol.2017.5819] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
10 Leto SM, Trusolino L. Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. J Mol Med (Berl) 2014;92:709-22. [PMID: 24811491 DOI: 10.1007/s00109-014-1161-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
11 Kastrisiou M, Zarkavelis G, Pentheroudakis G, Magklara A. Clinical Application of Next-Generation Sequencing as A Liquid Biopsy Technique in Advanced Colorectal Cancer: A Trick or A Treat? Cancers (Basel) 2019;11:E1573. [PMID: 31623125 DOI: 10.3390/cancers11101573] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
12 Bronte G, Silvestris N, Castiglia M, Galvano A, Passiglia F, Sortino G, Cicero G, Rolfo C, Peeters M, Bazan V, Fanale D, Giordano A, Russo A. New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS? Oncotarget 2015;6:24780-96. [PMID: 26318427 DOI: 10.18632/oncotarget.4959] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 9.2] [Reference Citation Analysis]
13 Cappuzzo F, Sacconi A, Landi L, Ludovini V, Biagioni F, D’Incecco A, Capodanno A, Salvini J, Corgna E, Cupini S. MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies. Clin Colorectal Cancer. 2014;13:37-45.e4. [PMID: 24503111 DOI: 10.1016/j.clcc.2013.11.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
14 Carvalho S, Levi-Schaffer F, Sela M, Yarden Y. Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. Br J Pharmacol 2016;173:1407-24. [PMID: 26833433 DOI: 10.1111/bph.13450] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
15 Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014;25:282-303. [PMID: 24651011 DOI: 10.1016/j.ccr.2014.02.025] [Cited by in Crossref: 537] [Cited by in F6Publishing: 490] [Article Influence: 67.1] [Reference Citation Analysis]
16 Dong Z, Kong L, Wan Z, Zhu F, Zhong M, Lv Y, Zhao P, Shi H. Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients. Sci Rep 2019;9:16894. [PMID: 31729406 DOI: 10.1038/s41598-019-53039-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Mannavola F, Salerno T, Passarelli A, Tucci M, Internò V, Silvestris F. Revisiting the Role of Exosomes in Colorectal Cancer: Where Are We Now?. Front Oncol 2019;9:521. [PMID: 31275854 DOI: 10.3389/fonc.2019.00521] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
18 Sartore-Bianchi A, Siena S, Tonini G, Bardelli A, Santini D. Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. Cancer Treat Rev 2016;51:54-62. [PMID: 27865140 DOI: 10.1016/j.ctrv.2016.10.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
19 Lee MKC, Loree JM. Current and emerging biomarkers in metastatic colorectal cancer. Curr Oncol 2019;26:S7-S15. [PMID: 31819705 DOI: 10.3747/co.26.5719] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
20 Lee TS, Song IH, Shin JI, Park YS, Kim JY, Kim KI, Lee YJ, Kang JH. PET Imaging Biomarkers of Anti-EGFR Immunotherapy in Esophageal Squamous Cell Carcinoma Models. Cells 2018;7:E187. [PMID: 30373221 DOI: 10.3390/cells7110187] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Buch I, Ferruz N, De Fabritiis G. Computational modeling of an epidermal growth factor receptor single-mutation resistance to cetuximab in colorectal cancer treatment. J Chem Inf Model 2013;53:3123-6. [PMID: 24219403 DOI: 10.1021/ci400456m] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
22 Saki M, Toulany M, Rodemann HP. Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells. Radiother Oncol 2013;108:473-8. [PMID: 23891090 DOI: 10.1016/j.radonc.2013.06.023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
23 Parisi A, Porzio G, Cannita K, Venditti O, Avallone A, Filippi R, Salvatore L, Tortora G, Ribelli M, Nigro O, Gelsomino F, Spallanzani A, Zurlo V, Leo S, Dell'Aquila E, Claudia F, Lombardi P, Keränen SR, Aimar G, Depetris I, Giampieri R, Morelli C, De Tursi M, Tinari N, Di Pietro FR, De Galitiis F, Zanaletti N, Troiani T, Vitale P, Garajova I, Ghidini M, Spinelli GP, Zoratto F, Roberto M, Ierino D, Petrillo A, D'Orazio C, Ficorella C, Cortellini A. Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study. Clin Colorectal Cancer 2021:S1533-0028(21)00068-2. [PMID: 34380594 DOI: 10.1016/j.clcc.2021.07.003] [Reference Citation Analysis]
24 Katayama Y, Yamada T, Tokuda S, Okura N, Nishioka N, Morimoto K, Tanimura K, Morimoto Y, Iwasaku M, Horinaka M, Sakai T, Kita K, Yano S, Takayama K. Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR ‐T790M mutation in non‐small cell lung cancer cells. Cancer Medicine. [DOI: 10.1002/cam4.4504] [Reference Citation Analysis]
25 Vemala RNG, Katti SV, Sirohi B, Manikandan D, Nandakumar G. Molecular Oncology in Management of Colorectal Cancer. Indian J Surg Oncol 2021;12:169-80. [PMID: 33994743 DOI: 10.1007/s13193-021-01289-6] [Reference Citation Analysis]
26 Arena S, Siravegna G, Mussolin B, Kearns JD, Wolf BB, Misale S, Lazzari L, Bertotti A, Trusolino L, Adjei AA, Montagut C, Di Nicolantonio F, Nering R, Bardelli A. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci Transl Med. 2016;8:324ra14. [PMID: 26843189 DOI: 10.1126/scitranslmed.aad5640] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 9.3] [Reference Citation Analysis]
27 Li Z, Chen Y, Ren WU, Hu S, Tan Z, Wang Y, Chen Y, Zhang J, Wu J, Li T, Xu J, Ying X. Transcriptome Alterations in Liver Metastases of Colorectal Cancer After Acquired Resistance to Cetuximab. Cancer Genomics Proteomics 2019;16:207-19. [PMID: 31018951 DOI: 10.21873/cgp.20126] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
28 Stepath M, Zülch B, Maghnouj A, Schork K, Turewicz M, Eisenacher M, Hahn S, Sitek B, Bracht T. Systematic Comparison of Label-Free, SILAC, and TMT Techniques to Study Early Adaption toward Inhibition of EGFR Signaling in the Colorectal Cancer Cell Line DiFi. J Proteome Res 2020;19:926-37. [DOI: 10.1021/acs.jproteome.9b00701] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
29 Boeckx C, Baay M, Wouters A, Specenier P, Vermorken JB, Peeters M, Lardon F. Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance. Oncologist 2013;18:850-64. [PMID: 23821327 DOI: 10.1634/theoncologist.2013-0013] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 6.8] [Reference Citation Analysis]
30 Sforza V, Martinelli E, Ciardiello F, Gambardella V, Napolitano S, Martini G, della Corte C, Cardone C, Ferrara ML, Reginelli A, Liguori G, Belli G, Troiani T. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol 2016; 22(28): 6345-6361 [PMID: 27605871 DOI: 10.3748/wjg.v22.i28.6345] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 56] [Article Influence: 10.0] [Reference Citation Analysis]
31 Zanella ER, Galimi F, Sassi F, Migliardi G, Cottino F, Leto SM, Lupo B, Erriquez J, Isella C, Comoglio PM. IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. Sci Transl Med. 2015;7:272ra12. [PMID: 25632036 DOI: 10.1126/scitranslmed.3010445] [Cited by in Crossref: 75] [Cited by in F6Publishing: 59] [Article Influence: 10.7] [Reference Citation Analysis]
32 Oh D, Bang Y. HER2-targeted therapies — a role beyond breast cancer. Nat Rev Clin Oncol 2020;17:33-48. [DOI: 10.1038/s41571-019-0268-3] [Reference Citation Analysis]
33 de Langen AJ, Jebbink M, Hashemi SMS, Kuiper JL, de Bruin-Visser J, Monkhorst K, Thunnissen E, Smit EF. Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment. Br J Cancer 2018;119:558-64. [PMID: 30061586 DOI: 10.1038/s41416-018-0194-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
34 Li QH, Wang YZ, Tu J, Liu CW, Yuan YJ, Lin R, He WL, Cai SR, He YL, Ye JN. Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. Gastroenterol Rep (Oxf) 2020;8:179-91. [PMID: 32665850 DOI: 10.1093/gastro/goaa026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
35 Graves-Deal R, Bogatcheva G, Rehman S, Lu Y, Higginbotham JN, Singh B. Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer. Oncotarget 2019;10:1320-33. [PMID: 30863492 DOI: 10.18632/oncotarget.26663] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
36 Watanabe S, Yonesaka K, Tanizaki J, Nonagase Y, Takegawa N, Haratani K, Kawakami H, Hayashi H, Takeda M, Tsurutani J, Nakagawa K. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer. Cancer Med 2019;8:1258-68. [PMID: 30701699 DOI: 10.1002/cam4.1995] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
37 Martin V, Landi L, Molinari F, Fountzilas G, Geva R, Riva A, Saletti P, De Dosso S, Spitale A, Tejpar S, Kalogeras KT, Mazzucchelli L, Frattini M, Cappuzzo F. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br J Cancer. 2013;108:668-675. [PMID: 23348520 DOI: 10.1038/bjc.2013.4] [Cited by in Crossref: 90] [Cited by in F6Publishing: 85] [Article Influence: 10.0] [Reference Citation Analysis]
38 Rooney M, Devarakonda S, Govindan R. Genomics of squamous cell lung cancer. Oncologist 2013;18:707-16. [PMID: 23728941 DOI: 10.1634/theoncologist.2013-0063] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
39 Lee SY, Oh SC. Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer. Biomed Res Int. 2016;2016:7590245. [PMID: 27127793 DOI: 10.1155/2016/7590245] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
40 Takegawa N, Yonesaka K. HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy. Clinical Colorectal Cancer 2017;16:247-51. [DOI: 10.1016/j.clcc.2017.03.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
41 Zhang K, Wang H. [Role of HER2 in NSCLC]. Zhongguo Fei Ai Za Zhi 2015;18:644-51. [PMID: 26483338 DOI: 10.3779/j.issn.1009-3419.2015.10.08] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Zhang H, Yuan L, Liu L, Yan C, Cheng J, Fu Q, Tong Z, Jiang W, Zheng Y, Zhao P, Zhang G, Fang W. Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab. BMC Cancer 2020;20:416. [PMID: 32404198 DOI: 10.1186/s12885-020-06909-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Juliachs M, Castillo-Ávila W, Vidal A, Piulats JM, Garcia Del Muro X, Condom E, Hernández-Losa J, Teixidó C, Pandiella A, Graupera M, Casanovas O, Germà JR, Villanueva A, Viñals F. ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. Int J Cancer 2013;133:235-46. [PMID: 23292912 DOI: 10.1002/ijc.28009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
44 Akkad J, Bochum S, Martens UM. Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies. Langenbecks Arch Surg 2015;400:129-43. [DOI: 10.1007/s00423-015-1276-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
45 Raghav K, Loree JM, Morris JS, Overman MJ, Yu R, Meric-bernstam F, Menter D, Korphaisarn K, Kee B, Muranyi A, Singh S, Routbort M, Chen K, Shaw KR, Katkhuda R, Shanmugam K, Maru D, Fakih M, Kopetz S. Validation of HER2 Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precision Oncology 2019. [DOI: 10.1200/po.18.00226] [Cited by in Crossref: 12] [Article Influence: 4.0] [Reference Citation Analysis]
46 Van Emburgh BO, Arena S, Siravegna G, Lazzari L, Crisafulli G, Corti G, Mussolin B, Baldi F, Buscarino M, Bartolini A, Valtorta E, Vidal J, Bellosillo B, Germano G, Pietrantonio F, Ponzetti A, Albanell J, Siena S, Sartore-Bianchi A, Di Nicolantonio F, Montagut C, Bardelli A. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat Commun 2016;7:13665. [PMID: 27929064 DOI: 10.1038/ncomms13665] [Cited by in Crossref: 100] [Cited by in F6Publishing: 90] [Article Influence: 16.7] [Reference Citation Analysis]
47 Krentel F, Singer F, Rosano-Gonzalez ML, Gibb EA, Liu Y, Davicioni E, Keller N, Stekhoven DJ, Kruithof-de Julio M, Seiler R. A showcase study on personalized in silico drug response prediction based on the genetic landscape of muscle invasive bladder cancer. Sci Rep 2021;11:5849. [PMID: 33712636 DOI: 10.1038/s41598-021-85151-3] [Reference Citation Analysis]
48 Jachimowicz RD, Borchmann S, Rothe A. Multi-specific antibodies for cancer immunotherapy. BioDrugs 2014;28:331-43. [PMID: 24638872 DOI: 10.1007/s40259-014-0091-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
49 Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, Bardelli A. Acquired resistance to EGFR-targeted therapies in colorectal cancer. Mol Oncol 2014;8:1084-94. [PMID: 24913799 DOI: 10.1016/j.molonc.2014.05.003] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 9.9] [Reference Citation Analysis]
50 Gong J, Cho M, Fakih M. RAS and BRAF in metastatic colorectal cancer management. J Gastrointest Oncol 2016;7:687-704. [PMID: 27747083 DOI: 10.21037/jgo.2016.06.12] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
51 De Cuyper A, Van Den Eynde M, Machiels JP. HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer. Clin Colorectal Cancer 2020;19:65-72. [PMID: 32229076 DOI: 10.1016/j.clcc.2020.02.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
52 Martini G, Ciardiello D, Vitiello PP, Napolitano S, Cardone C, Cuomo A, Troiani T, Ciardiello F, Martinelli E. Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? Cancer Treat Rev 2020;86:102023. [PMID: 32474402 DOI: 10.1016/j.ctrv.2020.102023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
53 Ugurluer G, Ozsahin M. Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer. Expert Opinion on Investigational Drugs 2014;23:1637-54. [DOI: 10.1517/13543784.2014.951435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
54 Hafeez U, Parslow AC, Gan HK, Scott AM. New insights into ErbB3 function and therapeutic targeting in cancer. Expert Rev Anticancer Ther 2020;20:1057-74. [PMID: 32981377 DOI: 10.1080/14737140.2020.1829485] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
55 Lazrek Y, Dubreuil O, Garambois V, Gaborit N, Larbouret C, Le Clorennec C, Thomas G, Leconet W, Jarlier M, Pugnière M. Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation. Neoplasia. 2013;15:335-347. [PMID: 23479511 DOI: 10.1593/neo.121960] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
56 Sawada T, Yamamoto E, Suzuki H, Nojima M, Maruyama R, Shioi Y, Akasaka R, Kamimae S, Harada T, Ashida M. Association between genomic alterations and metastatic behavior of colorectal cancer identified by array-based comparative genomic hybridization. Genes Chromosomes Cancer. 2013;52:140-149. [PMID: 23073979 DOI: 10.1002/gcc.22013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
57 Lim SW, Kim HR, Kim HY, Huh JW, Kim YJ, Shin JH, Suh SP, Ryang DW, Kim HR, Shin MG. Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor. Cell Oncol (Dordr). 2013;36:311-321. [PMID: 23722824 DOI: 10.1007/s13402-013-0136-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
58 Jiang N, Wang D, Hu Z, Shin HJ, Qian G, Rahman MA, Zhang H, Amin AR, Nannapaneni S, Wang X, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, Ma J, Chen ZG, Saba NF. Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma. Mol Cancer Ther 2014;13:1826-36. [PMID: 24748655 DOI: 10.1158/1535-7163.MCT-13-1093] [Cited by in Crossref: 46] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
59 Lin PH, Tseng CL, Cheng YC, Ho CH, Chen SC, Wang Y, Liu E, Issafras H, Jiang W. Distinguishing features of a novel humanized anti-EGFR monoclonal antibody based on cetuximab with superior antitumor efficacy. Expert Opin Biol Ther 2021;21:1491-507. [PMID: 34632911 DOI: 10.1080/14712598.2021.1988072] [Reference Citation Analysis]
60 Zhang K, Jones L, Lim S, Maher CA, Adkins D, Lewis J, Kimple RJ, Fertig EJ, Chung CH, Van Tine BA, Ellis MJ, Herrlich A, Michel LS. Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC. Oncotarget 2014;5:9281-94. [PMID: 25238142 DOI: 10.18632/oncotarget.2423] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
61 Lee SK, Hwang JH, Choi KY. Interaction of the Wnt/β-catenin and RAS-ERK pathways involving co-stabilization of both β-catenin and RAS plays important roles in the colorectal tumorigenesis. Adv Biol Regul 2018;68:46-54. [PMID: 29449169 DOI: 10.1016/j.jbior.2018.01.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
62 Zhu Y, Bassoff N, Reinshagen C, Bhere D, Nowicki MO, Lawler SE, Roux J, Shah K. Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors. Sci Rep 2017;7:2602. [PMID: 28572590 DOI: 10.1038/s41598-017-02483-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
63 Yeh SJ, Hsu BJ, Chen BS. Systems Medicine Design for Triple-Negative Breast Cancer and Non-Triple-Negative Breast Cancer Based on Systems Identification and Carcinogenic Mechanisms. Int J Mol Sci 2021;22:3083. [PMID: 33802957 DOI: 10.3390/ijms22063083] [Reference Citation Analysis]
64 El Dika I, Ilson DH. Current and future therapies for targeting HER2 mutations in gastrointestinal cancer. Expert Rev Anticancer Ther 2018;18:1085-92. [PMID: 30092682 DOI: 10.1080/14737140.2018.1510324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
65 Kato R, Haratani K, Hayashi H, Sakai K, Sakai H, Kawakami H, Tanaka K, Takeda M, Yonesaka K, Nishio K, Nakagawa K. Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts. Br J Cancer 2021;124:914-24. [PMID: 33299131 DOI: 10.1038/s41416-020-01201-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
66 Larbouret C, Gaborit N, Poul MA, Pèlegrin A, Chardès T. [The HER3/ERBB3 receptor: the dark side of the ERBB planet]. Med Sci (Paris) 2015;31:465-8. [PMID: 26059291 DOI: 10.1051/medsci/20153105002] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
67 Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell. 2011;20:472-486. [PMID: 22014573 DOI: 10.1016/j.ccr.2011.09.003] [Cited by in Crossref: 249] [Cited by in F6Publishing: 204] [Article Influence: 24.9] [Reference Citation Analysis]
68 Russo R, Matrone N, Belli V, Ciardiello D, Valletta M, Esposito S, Pedone PV, Ciardiello F, Troiani T, Chambery A. Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells. Cancers (Basel) 2019;11:E1430. [PMID: 31557914 DOI: 10.3390/cancers11101430] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
69 Jeong JH, Kim J, Hong YS, Kim D, Kim JE, Kim SY, Kim KP, Yoon YK, Kim D, Chun SM. HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF. Clin Colorectal Cancer. 2017;16:e147-e152. [PMID: 28223103 DOI: 10.1016/j.clcc.2017.01.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
70 Rembielak AI, Jain P, Jackson AS, Green MM, Santorelli GR, Whitfield GA, Crellin A, Garcia-Alonso A, Radhakrishna G, Cullen J, Taylor MB, Swindell R, West CM, Valle J, Saleem A, Price PM. Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study. Transl Oncol 2014;7:55-64. [PMID: 24772208 DOI: 10.1593/tlo.13724] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
71 Markovic A, Chung CH. Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma. Expert Rev Anticancer Ther 2012;12:1149-59. [PMID: 23098115 DOI: 10.1586/era.12.91] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 4.2] [Reference Citation Analysis]
72 Mirone G, Shukla A, Marfe G. Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer. Crit Rev Oncol Hematol 2016;97:85-95. [PMID: 26364891 DOI: 10.1016/j.critrevonc.2015.08.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
73 Jia J, Morse MA, Nagy RJ, Lanman RB, Strickler JH. Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer. Front Oncol 2018;8:305. [PMID: 30211110 DOI: 10.3389/fonc.2018.00305] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
74 Yang L, Li Y, Bhattacharya A, Zhang Y. Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant. EBioMedicine 2015;2:396-405. [PMID: 26086037 DOI: 10.1016/j.ebiom.2015.03.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
75 Rong C, Muller MF, Xiang F, Jensen A, Weichert W, Major G, Plinkert PK, Hess J, Affolter A. Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC. Br J Cancer 2020;123:288-97. [PMID: 32424150 DOI: 10.1038/s41416-020-0892-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
76 Kumar R, George B, Campbell MR, Verma N, Paul AM, Melo-Alvim C, Ribeiro L, Pillai MR, da Costa LM, Moasser MM. HER family in cancer progression: From discovery to 2020 and beyond. Adv Cancer Res 2020;147:109-60. [PMID: 32593399 DOI: 10.1016/bs.acr.2020.04.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
77 Brammeld JS, Petljak M, Martincorena I, Williams SP, Alonso LG, Dalmases A, Bellosillo B, Robles-Espinoza CD, Price S, Barthorpe S, Tarpey P, Alifrangis C, Bignell G, Vidal J, Young J, Stebbings L, Beal K, Stratton MR, Saez-Rodriguez J, Garnett M, Montagut C, Iorio F, McDermott U. Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations. Genome Res 2017;27:613-25. [PMID: 28179366 DOI: 10.1101/gr.213546.116] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
78 Perkins G, Pilati C, Blons H, Laurent-Puig P. Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer. Pharmacogenomics 2014;15:1043-52. [PMID: 24956256 DOI: 10.2217/pgs.14.66] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
79 Rankin A, Klempner SJ, Erlich R, Sun JX, Grothey A, Fakih M, George TJ Jr, Lee J, Ross JS, Stephens PJ, Miller VA, Ali SM, Schrock AB. Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. Oncologist 2016;21:1306-14. [PMID: 27682134 DOI: 10.1634/theoncologist.2016-0148] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
80 Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, McCall SJ, Penault-Llorca F, Srock S, Bardelli A, Trusolino L. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018;29:1108-1119. [PMID: 29659677 DOI: 10.1093/annonc/mdy100] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 24.3] [Reference Citation Analysis]
81 De Pauw I, Lardon F, Van den Bossche J, Baysal H, Fransen E, Deschoolmeester V, Pauwels P, Peeters M, Vermorken JB, Wouters A. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines. Mol Oncol 2018;12:830-54. [PMID: 29603584 DOI: 10.1002/1878-0261.12197] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
82 Antoniotti C, Ongaro E, Falcone A, Cremolini C. The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer. Int J Mol Sci 2018;19:E2298. [PMID: 30081606 DOI: 10.3390/ijms19082298] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
83 Esposito C, Rachiglio AM, La Porta ML, Sacco A, Roma C, Iannaccone A, Tatangelo F, Forgione L, Pasquale R, Barbaro A, Botti G, Ciardiello F, Normanno N. The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. Cancer Biol Ther 2013;14:1143-6. [PMID: 24025416 DOI: 10.4161/cbt.26340] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 4.7] [Reference Citation Analysis]
84 Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, Bernards R, Bardelli A. Precision oncology in metastatic colorectal cancer - from biology to medicine. Nat Rev Clin Oncol 2021;18:506-25. [PMID: 33864051 DOI: 10.1038/s41571-021-00495-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
85 Greally M, Kelly CM, Cercek A. HER2: An emerging target in colorectal cancer. Current Problems in Cancer 2018;42:560-71. [DOI: 10.1016/j.currproblcancer.2018.07.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
86 Huang W, Chen Y, Chang W, Ren L, Tang W, Zheng P, Wu Q, Liu T, Liu Y, Wei Y, Xu J. HER2 positivity as a biomarker for poor prognosis and unresponsiveness to anti-EGFR therapy in colorectal cancer. J Cancer Res Clin Oncol 2021. [PMID: 34156520 DOI: 10.1007/s00432-021-03655-x] [Reference Citation Analysis]
87 Vakiani E. Molecular Testing of Colorectal Cancer in the Modern Era: What Are We Doing and Why? Surg Pathol Clin 2017;10:1009-20. [PMID: 29103530 DOI: 10.1016/j.path.2017.07.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
88 Sclafani F, Roy A, Cunningham D, Wotherspoon A, Peckitt C, Gonzalez de Castro D, Tabernero J, Glimelius B, Cervantes A, Eltahir Z. HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. Ann Oncol. 2013;24:3123-3128. [PMID: 24146218 DOI: 10.1093/annonc/mdt408] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
89 Schütte M, Risch T, Abdavi-Azar N, Boehnke K, Schumacher D, Keil M, Yildiriman R, Jandrasits C, Borodina T, Amstislavskiy V, Worth CL, Schweiger C, Liebs S, Lange M, Warnatz HJ, Butcher LM, Barrett JE, Sultan M, Wierling C, Golob-Schwarzl N, Lax S, Uranitsch S, Becker M, Welte Y, Regan JL, Silvestrov M, Kehler I, Fusi A, Kessler T, Herwig R, Landegren U, Wienke D, Nilsson M, Velasco JA, Garin-Chesa P, Reinhard C, Beck S, Schäfer R, Regenbrecht CR, Henderson D, Lange B, Haybaeck J, Keilholz U, Hoffmann J, Lehrach H, Yaspo ML. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat Commun 2017;8:14262. [PMID: 28186126 DOI: 10.1038/ncomms14262] [Cited by in Crossref: 145] [Cited by in F6Publishing: 134] [Article Influence: 29.0] [Reference Citation Analysis]
90 Shaib W, Kono S, Saba N. Antiepidermal growth factor receptor therapy in squamous cell carcinoma of the head and neck. J Oncol 2012;2012:521215. [PMID: 22778735 DOI: 10.1155/2012/521215] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
91 Shitara K, Yuki S, Yamazaki K, Naito Y, Fukushima H, Komatsu Y, Yasui H, Takano T, Muro K. Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. J Cancer Res Clin Oncol 2013;139:595-603. [PMID: 23250506 DOI: 10.1007/s00432-012-1349-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
92 Psyrri A, Seiwert TY, Jimeno A. Molecular pathways in head and neck cancer: EGFR, PI3K, and more. Am Soc Clin Oncol Educ Book 2013;:246-55. [PMID: 23714515 DOI: 10.14694/EdBook_AM.2013.33.246] [Cited by in Crossref: 8] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
93 Rao SD, Fury MG, Pfister DG. Molecular-targeted therapies in head and neck cancer. Semin Radiat Oncol 2012;22:207-13. [PMID: 22687945 DOI: 10.1016/j.semradonc.2012.03.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
94 Wang J, Xing B, Liu W, Li J, Wang X, Li J, Yang J, Ji C, Li Z, Dong B, Gao J, Shen L. Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis. Theranostics 2019;9:3485-500. [PMID: 31281492 DOI: 10.7150/thno.32033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
95 Bosch-Vilaró A, Jacobs B, Pomella V, Abbasi Asbagh L, Kirkland R, Michel J, Singh S, Liu X, Kim P, Weitsman G, Barber PR, Vojnovic B, Ng T, Tejpar S. Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells. Oncotarget 2017;8:4277-88. [PMID: 28032592 DOI: 10.18632/oncotarget.13834] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
96 Faber AC, Ebi H, Costa C, Engelman JA. Apoptosis In Targeted Therapy Responses. Current Challenges in Personalized Cancer Medicine. Elsevier; 2012. pp. 519-42. [DOI: 10.1016/b978-0-12-397927-8.00016-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
97 Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol 2019;30:243-9. [PMID: 30462160 DOI: 10.1093/annonc/mdy509] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 34.5] [Reference Citation Analysis]
98 Seow HF, Yip WK, Fifis T. Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco Targets Ther 2016;9:1899-920. [PMID: 27099521 DOI: 10.2147/OTT.S95101] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
99 Lubner SJ, Uboha NV, Deming DA. Primary and acquired resistance to biologic therapies in gastrointestinal cancers. J Gastrointest Oncol 2017;8:499-512. [PMID: 28736637 DOI: 10.21037/jgo.2017.01.16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
100 Ma J, Lyu H, Huang J, Liu B. Targeting of erbB3 receptor to overcome resistance in cancer treatment. Mol Cancer. 2014;13:105. [PMID: 24886126 DOI: 10.1186/1476-4598-13-105] [Cited by in Crossref: 94] [Cited by in F6Publishing: 93] [Article Influence: 11.8] [Reference Citation Analysis]
101 Pirpour Tazehkand A, Akbarzadeh M, Velaie K, Sadeghi MR, Samadi N. The role of Her2-Nrf2 axis in induction of oxaliplatin resistance in colon cancer cells. Biomed Pharmacother 2018;103:755-66. [PMID: 29684854 DOI: 10.1016/j.biopha.2018.04.105] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
102 Giopanou I, Pintzas A. RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies. Crit Rev Oncol Hematol 2020;146:102859. [PMID: 31927392 DOI: 10.1016/j.critrevonc.2019.102859] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
103 Van Pham P, Vu NB, Duong TT, Nguyen TT, Truong NH, Phan NL, Vuong TG, Pham VQ, Nguyen HM, Nguyen KT, Nguyen NT, Nguyen KG, Khat LT, Van Le D, Truong KD, Phan NK. Suppression of human breast tumors in NOD/SCID mice by CD44 shRNA gene therapy combined with doxorubicin treatment. Onco Targets Ther 2012;5:77-84. [PMID: 22649280 DOI: 10.2147/OTT.S30609] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
104 Thwe AM, Mossey P, Ellis IR. Effect of tyrosine kinase inhibitors on cell migration and epithelial-to-mesenchymal transition in Asian head and neck cancer cell lines. J Oral Pathol Med 2021. [PMID: 34358366 DOI: 10.1111/jop.13230] [Reference Citation Analysis]
105 Ree AH, Kristensen AT, Saelen MG, de Wijn R, Edvardsen H, Jovanovic J, Abrahamsen TW, Dueland S, Flatmark K. Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer. PLoS One 2012;7:e50806. [PMID: 23226389 DOI: 10.1371/journal.pone.0050806] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
106 Klupp F, Sass M, Bergmann F, Khajeh E, Ghamarnejad O, Hassenpflug M, Mehrabi A, Kulu Y. Impact of EGFR and EGFR ligand expression on treatment response in patients with metastatic colorectal cancer. Oncol Lett 2021;21:448. [PMID: 33868486 DOI: 10.3892/ol.2021.12709] [Reference Citation Analysis]
107 Liu Y, Zhang Y, Zhang L, Liu B, Wang Y, Zhou X, Li Y, Zhao Q, Gong Y, Zhou L, Zhu J, Ding Z, Wang J, Peng F, Huang M, Li L, Ren L, Lu Y. Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports. Oncotarget. 2017;8:49680-49688. [PMID: 28591695 DOI: 10.18632/oncotarget.17915] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
108 Pagliarini R, Shao W, Sellers WR. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep. 2015;16:280-296. [PMID: 25680965 DOI: 10.15252/embr.201439949] [Cited by in Crossref: 132] [Cited by in F6Publishing: 118] [Article Influence: 18.9] [Reference Citation Analysis]
109 Zhu J, Strickler JH. Clinical applications of liquid biopsies in gastrointestinal oncology. J Gastrointest Oncol 2016;7:675-86. [PMID: 27747082 DOI: 10.21037/jgo.2016.08.08] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
110 Monteleone F, Rosa R, Vitale M, D'ambrosio C, Succoio M, Formisano L, Nappi L, Romano MF, Scaloni A, Tortora G, Bianco R, Zambrano N. Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody. Proteomics 2013;13:866-77. [DOI: 10.1002/pmic.201200303] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
111 Zhou Q, Perakis SO, Ulz P, Mohan S, Riedl JM, Talakic E, Lax S, Tötsch M, Hoefler G, Bauernhofer T, Pichler M, Gerger A, Geigl JB, Heitzer E, Speicher MR. Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer. Genome Med 2020;12:20. [PMID: 32087735 DOI: 10.1186/s13073-020-0719-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
112 Kim HAJ, Shaikh MH, Lee M, Zeng PYF, Sorgini A, Akintola T, Deng X, Jarycki L, Khan H, MacNeil D, Khan MI, Mendez A, Yoo J, Fung K, Lang P, Palma DA, Patel K, Mymryk JS, Barrett JW, Boutros PC, Morris LGT, Nichols AC. 3p Arm Loss and Survival in Head and Neck Cancer: An Analysis of TCGA Dataset. Cancers (Basel) 2021;13:5313. [PMID: 34771477 DOI: 10.3390/cancers13215313] [Reference Citation Analysis]
113 Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532-536. [PMID: 22722830 DOI: 10.1038/nature 11156] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
114 Riaz N, Morris LG, Lee W, Chan TA. Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. Genes Dis. 2014;1:75-86. [PMID: 25642447 DOI: 10.1016/j.gendis.2014.07.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 7.8] [Reference Citation Analysis]
115 Lièvre A, Ouine B, Canet J, Cartier A, Amar Y, Cacheux W, Mariani O, Guimbaud R, Selves J, Lecomte T, Guyetant S, Bieche I, Berger F, de Koning L. Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma. Br J Cancer 2017;117:1819-27. [PMID: 29024937 DOI: 10.1038/bjc.2017.353] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
116 Khelwatty SA, Essapen S, Seddon AM, Fan Z, Modjtahedi H. Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. Br J Cancer 2015;113:1010-9. [PMID: 26372697 DOI: 10.1038/bjc.2015.319] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
117 Parikh A, Atreya C, Korn WM, Venook AP. Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. J Natl Compr Canc Netw. 2017;15:3-8. [PMID: 28040715 DOI: 10.6004/jnccn.2017.0002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
118 Chen D, Huang X, Cai J, Guo S, Qian W, Wery JP, Li QX. A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations. Oncotarget 2015;6:40815-21. [PMID: 26512781 DOI: 10.18632/oncotarget.5886] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
119 Vangala D, Ladigan S, Liffers ST, Noseir S, Maghnouj A, Götze TM, Verdoodt B, Klein-Scory S, Godfrey L, Zowada MK, Huerta M, Edelstein DL, de Villarreal JM, Marqués M, Kumbrink J, Jung A, Schiergens T, Werner J, Heinemann V, Stintzing S, Lindoerfer D, Mansmann U, Pohl M, Teschendorf C, Bernhardt C, Wolters H, Stern J, Usta S, Viebahn R, Admard J, Casadei N, Fröhling S, Ball CR, Siveke JT, Glimm H, Tannapfel A, Schmiegel W, Hahn SA. Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models. Genome Med 2021;13:116. [PMID: 34271981 DOI: 10.1186/s13073-021-00926-7] [Reference Citation Analysis]
120 Vidal J, Taus A, Montagut C. Dynamic Treatment Stratification Using ctDNA. Recent Results Cancer Res 2020;215:263-73. [PMID: 31605234 DOI: 10.1007/978-3-030-26439-0_14] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
121 Yonesaka K. HER2-/HER3-Targeting Antibody-Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors. Cancers (Basel) 2021;13:1047. [PMID: 33801379 DOI: 10.3390/cancers13051047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
122 Salem ME, Puccini A, Tie J. Redefining Colorectal Cancer by Tumor Biology. Am Soc Clin Oncol Educ Book 2020;40:1-13. [PMID: 32207671 DOI: 10.1200/EDBK_279867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
123 Qian G, Jiang N, Wang D, Newman S, Kim S, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, Chen ZG, Saba NF. Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma. Cancer 2015;121:3600-11. [PMID: 26195293 DOI: 10.1002/cncr.29549] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
124 Rayavarapu RR, Heiden B, Pagani N, Shaw MM, Shuff S, Zhang S, Schafer ZT. The role of multicellular aggregation in the survival of ErbB2-positive breast cancer cells during extracellular matrix detachment. J Biol Chem 2015;290:8722-33. [PMID: 25681438 DOI: 10.1074/jbc.M114.612754] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 3.9] [Reference Citation Analysis]
125 Möller Y, Morkel M, Schmid J, Beyes S, Hendrick J, Strotbek M, Riemer P, Schmid S, Schmitt LC, Kontermann R, Mürdter T, Schwab M, Sers C, Olayioye MA. Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling. Oncotarget 2016;7:53526-39. [PMID: 27447549 DOI: 10.18632/oncotarget.10658] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
126 Ricciardi GR, Russo A, Franchina T, Ferraro G, Zanghì M, Picone A, Scimone A, Adamo V. NSCLC and HER2: between lights and shadows. J Thorac Oncol 2014;9:1750-62. [PMID: 25247338 DOI: 10.1097/JTO.0000000000000379] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
127 Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, Salgia R. Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014;5:1392-433. [PMID: 24722523 DOI: 10.18632/oncotarget.1891] [Cited by in Crossref: 111] [Cited by in F6Publishing: 110] [Article Influence: 15.9] [Reference Citation Analysis]
128 Khan KH, Cunningham D, Werner B, Vlachogiannis G, Spiteri I, Heide T, Mateos JF, Vatsiou A, Lampis A, Damavandi MD, Lote H, Huntingford IS, Hedayat S, Chau I, Tunariu N, Mentrasti G, Trevisani F, Rao S, Anandappa G, Watkins D, Starling N, Thomas J, Peckitt C, Khan N, Rugge M, Begum R, Hezelova B, Bryant A, Jones T, Proszek P, Fassan M, Hahne JC, Hubank M, Braconi C, Sottoriva A, Valeri N. Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. Cancer Discov 2018;8:1270-85. [PMID: 30166348 DOI: 10.1158/2159-8290.CD-17-0891] [Cited by in Crossref: 114] [Cited by in F6Publishing: 65] [Article Influence: 28.5] [Reference Citation Analysis]
129 Shaib W, Mahajan R, El-Rayes B. Markers of resistance to anti-EGFR therapy in colorectal cancer. J Gastrointest Oncol 2013;4:308-18. [PMID: 23997942 DOI: 10.3978/j.issn.2078-6891.2013.029] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
130 Vecchione L, Saridaki Z, Tejpar S. Clinical Implications and Quality Assurance of Molecular Testing for EGFR-Targeting Agents in Colorectal Cancer. Curr Colorectal Cancer Rep 2012;8:42-50. [DOI: 10.1007/s11888-011-0112-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
131 Bansal M, Yang J, Karan C, Menden MP, Costello JC, Tang H, Xiao G, Li Y, Allen J, Zhong R, Chen B, Kim M, Wang T, Heiser LM, Realubit R, Mattioli M, Alvarez MJ, Shen Y, Gallahan D, Singer D, Saez-Rodriguez J, Xie Y, Stolovitzky G, Califano A; NCI-DREAM Community., NCI-DREAM Community. A community computational challenge to predict the activity of pairs of compounds. Nat Biotechnol 2014;32:1213-22. [PMID: 25419740 DOI: 10.1038/nbt.3052] [Cited by in Crossref: 170] [Cited by in F6Publishing: 139] [Article Influence: 21.3] [Reference Citation Analysis]
132 Guan JL, Liu JH, Wang Q, Cong YW, Chen YX, Huang KF, Huang ML, Huang L. Response of human epidermal growth factor receptor 2-positive colorectal cancer to lapatinib monotherapy: A case report. World J Gastrointest Oncol 2020; 12(9): 1065-1072 [PMID: 33005299 DOI: 10.4251/wjgo.v12.i9.1065] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
133 Fang RH, Zhang L. Combinatorial nanotherapeutics: rewiring, then killing, cancer cells. Sci Signal 2014;7:pe13. [PMID: 24825918 DOI: 10.1126/scisignal.2005386] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
134 Catenacci DVT, Liao WL, Zhao L, Whitcomb E, Henderson L, O'Day E, Xu P, Thyparambil S, Krizman D, Bengali K, Uzzell J, Darfler M, Cecchi F, Blackler A, Bang YJ, Hart J, Xiao SY, Lee SM, Burrows J, Hembrough T. Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH. Gastric Cancer 2016;19:1066-79. [PMID: 26581548 DOI: 10.1007/s10120-015-0566-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
135 Zhai Z, Yu X, Yang B, Zhang Y, Zhang L, Li X, Sun H. Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance. Semin Cell Dev Biol 2017;64:107-15. [PMID: 27578007 DOI: 10.1016/j.semcdb.2016.08.033] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
136 Goffin JR, Zbuk K. Epidermal growth factor receptor: pathway, therapies, and pipeline. Clin Ther 2013;35:1282-303. [PMID: 24054705 DOI: 10.1016/j.clinthera.2013.08.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
137 Cereda M, Gambardella G, Benedetti L, Iannelli F, Patel D, Basso G, Guerra RF, Mourikis TP, Puccio I, Sinha S, Laghi L, Spencer J, Rodriguez-Justo M, Ciccarelli FD. Patients with genetically heterogeneous synchronous colorectal cancer carry rare damaging germline mutations in immune-related genes. Nat Commun 2016;7:12072. [PMID: 27377421 DOI: 10.1038/ncomms12072] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
138 Uribe ML, Marrocco I, Yarden Y. EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers (Basel) 2021;13:2748. [PMID: 34206026 DOI: 10.3390/cancers13112748] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Li HS, Yang LL, Zhang MY, Cheng K, Chen Y, Liu JY. Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review. Front Oncol 2020;10:548867. [PMID: 33194604 DOI: 10.3389/fonc.2020.548867] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
140 Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, Buscarino M, Lazzari L, Sartore-Bianchi A. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med. 2014;6:224ra26. [PMID: 24553387 DOI: 10.1126/scitranslmed.3007947] [Cited by in Crossref: 174] [Cited by in F6Publishing: 157] [Article Influence: 21.8] [Reference Citation Analysis]
141 Wang R, Bhattacharya R, Ye X, Fan F, Boulbes DR, Ellis LM. Endothelial Cells Promote Colorectal Cancer Cell Survival by Activating the HER3-AKT Pathway in a Paracrine Fashion. Mol Cancer Res. 2019;17:20-29. [PMID: 30131447 DOI: 10.1158/1541-7786.mcr-18-0341] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
142 Yang X, Zhang X, Fu ML, Weichselbaum RR, Gajewski TF, Guo Y, Fu YX. Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell 2014;25:37-48. [PMID: 24434209 DOI: 10.1016/j.ccr.2013.12.004] [Cited by in Crossref: 168] [Cited by in F6Publishing: 157] [Article Influence: 21.0] [Reference Citation Analysis]
143 Fayette J, Wirth L, Oprean C, Udrea A, Jimeno A, Rischin D, Nutting C, Harari PM, Csoszi T, Cernea D, O'Brien P, Hanley WD, Kapp AV, Anderson M, Penuel E, McCall B, Pirzkall A, Vermorken JB. Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). Front Oncol 2016;6:232. [PMID: 27843803 DOI: 10.3389/fonc.2016.00232] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 8.5] [Reference Citation Analysis]
144 Korphaisarn K, Loree JM, Nguyen V, Coulson R, Holla V, Litzenburger BC, Chen K, Mills GB, Maru DM, Meric-Bernstan F, Shaw KRM, Kopetz S. Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature. Oncotarget 2017;8:57882-8. [PMID: 28915719 DOI: 10.18632/oncotarget.18357] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
145 Anastasi S, Lamberti D, Alemà S, Segatto O. Regulation of the ErbB network by the MIG6 feedback loop in physiology, tumor suppression and responses to oncogene-targeted therapeutics. Semin Cell Dev Biol 2016;50:115-24. [PMID: 26456277 DOI: 10.1016/j.semcdb.2015.10.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
146 Kawakami H, Okamoto I, Yonesaka K, Okamoto K, Shibata K, Shinkai Y, Sakamoto H, Kitano M, Tamura T, Nishio K, Nakagawa K. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget 2014;5:11847-56. [PMID: 25474137 DOI: 10.18632/oncotarget.2663] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 7.6] [Reference Citation Analysis]
147 Bardelli A, Jänne PA. The road to resistance: EGFR mutation and cetuximab. Nat Med 2012;18:199-200. [DOI: 10.1038/nm.2646] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
148 Claus J, Patel G, Ng T, Parker PJ. A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy. Biochem Soc Trans 2014;42:831-6. [PMID: 25109965 DOI: 10.1042/BST20140043] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
149 Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. 2012;2:922-933. [PMID: 22956644 DOI: 10.1158/2159-8290.cd-12-0108] [Cited by in Crossref: 451] [Cited by in F6Publishing: 267] [Article Influence: 45.1] [Reference Citation Analysis]
150 Gaiani F, Marchesi F, Negri F, Greco L, Malesci A, de'Angelis GL, Laghi L. Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes. Int J Mol Sci 2021;22:5246. [PMID: 34063506 DOI: 10.3390/ijms22105246] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
151 Li X, Duan Y, Qiao C, Zhou T, Yu M, Geng J, Feng J, Shen B, Lv M, Li Y. Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers. Technol Cancer Res Treat 2016;15:573-82. [PMID: 26041400 DOI: 10.1177/1533034615588422] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
152 Huang S, Peter Rodemann H, Harari PM. Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology. Recent Results Cancer Res 2016;198:45-87. [PMID: 27318681 DOI: 10.1007/978-3-662-49651-0_3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
153 Mouillet-Richard S. ERBB2 in anti-EGFR-resistant colorectal cancer: cancer stem cells come into play. Gut 2021:gutjnl-2020-323924. [PMID: 33619166 DOI: 10.1136/gutjnl-2020-323924] [Reference Citation Analysis]
154 Cohen RB. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). Cancer Treat Rev. 2014;40:567-577. [PMID: 24216225 DOI: 10.1016/j.ctrv.2013.10.002] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 9.7] [Reference Citation Analysis]
155 Vigneri PG, Tirrò E, Pennisi MS, Massimino M, Stella S, Romano C, Manzella L. The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy. Front Oncol. 2015;5:230. [PMID: 26528439 DOI: 10.3389/fonc.2015.00230] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 11.6] [Reference Citation Analysis]
156 Liu Z, Leng EC, Gunasekaran K, Pentony M, Shen M, Howard M, Stoops J, Manchulenko K, Razinkov V, Liu H, Fanslow W, Hu Z, Sun N, Hasegawa H, Clark R, Foltz IN, Yan W. A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J Biol Chem 2015;290:7535-62. [PMID: 25583986 DOI: 10.1074/jbc.M114.620260] [Cited by in Crossref: 52] [Cited by in F6Publishing: 38] [Article Influence: 7.4] [Reference Citation Analysis]
157 Yao S, Zheng P, Wu H, Song LM, Ying XF, Xing C, Li Y, Xiao ZQ, Zhou XN, Shen T, Chen L, Liu YH, Lai MD, Mei L, Gao TM, Li JM. Erbin interacts with c-Cbl and promotes tumourigenesis and tumour growth in colorectal cancer by preventing c-Cbl-mediated ubiquitination and down-regulation of EGFR. J Pathol 2015;236:65-77. [PMID: 25521828 DOI: 10.1002/path.4502] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
158 Lau DK, Burge M, Roy A, Chau I, Haller DG, Shapiro JD, Peeters M, Pavlakis N, Karapetis CS, Tebbutt NC, Segelov E, Price TJ. Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. Expert Rev Anticancer Ther 2020;20:251-70. [PMID: 32186929 DOI: 10.1080/14737140.2020.1744439] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Zhu G, Fan Z, Ding M, Zhang H, Mu L, Ding Y, Zhang Y, Jia B, Chen L, Chang Z, Wu W. An EGFR/PI3K/AKT axis promotes accumulation of the Rac1-GEF Tiam1 that is critical in EGFR-driven tumorigenesis. Oncogene 2015;34:5971-82. [DOI: 10.1038/onc.2015.45] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 8.0] [Reference Citation Analysis]
160 Burgy M, Jehl A, Conrad O, Foppolo S, Bruban V, Etienne-Selloum N, Jung AC, Masson M, Macabre C, Ledrappier S, Burckel H, Mura C, Noël G, Borel C, Fasquelle F, Onea MA, Chenard MP, Thiéry A, Dontenwill M, Martin S. Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma. Cancers (Basel) 2021;13:3038. [PMID: 34207120 DOI: 10.3390/cancers13123038] [Reference Citation Analysis]
161 Hirsch FR, Jänne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, Choy H, Kim ES, Paz-ares L, Gandara DR, Wu Y, Ahn M, Mitsudomi T, Shepherd FA, Mok TS. Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012. Journal of Thoracic Oncology 2013;8:373-84. [DOI: 10.1097/jto.0b013e31827ed0ff] [Cited by in Crossref: 83] [Cited by in F6Publishing: 44] [Article Influence: 9.2] [Reference Citation Analysis]
162 Fung NH, Grima CA, Widodo SS, Kaye AH, Whitehead CA, Stylli SS, Mantamadiotis T. Understanding and exploiting cell signalling convergence nodes and pathway cross-talk in malignant brain cancer. Cell Signal 2019;57:2-9. [PMID: 30710631 DOI: 10.1016/j.cellsig.2019.01.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
163 Cherri S, Libertini M, Zaniboni A. New drugs for the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2021; 13(11): 1551-1560 [PMID: 34853636 DOI: 10.4251/wjgo.v13.i11.1551] [Reference Citation Analysis]
164 Landi L, Cappuzzo F. HER2 and lung cancer. Expert Rev Anticancer Ther 2013;13:1219-28. [PMID: 24134423 DOI: 10.1586/14737140.2013.846830] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
165 Matikas A, Voutsina A, Trypaki M, Georgoulias V. Role of circulating free DNA in colorectal cancer. World J Gastrointest Oncol 2016; 8(12): 810-818 [PMID: 28035251 DOI: 10.4251/wjgo.v8.i12.810] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
166 Sveen A, Kopetz S, Lothe RA. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol 2020;17:11-32. [PMID: 31289352 DOI: 10.1038/s41571-019-0241-1] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 22.3] [Reference Citation Analysis]
167 Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther 2020;5:22. [PMID: 32296018 DOI: 10.1038/s41392-020-0116-z] [Cited by in Crossref: 130] [Cited by in F6Publishing: 140] [Article Influence: 65.0] [Reference Citation Analysis]
168 Martinelli E, Ciardiello D, Martini G, Troiani T, Cardone C, Vitiello PP, Normanno N, Rachiglio AM, Maiello E, Latiano T, De Vita F, Ciardiello F. Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. Ann Oncol 2020;31:30-40. [PMID: 31912793 DOI: 10.1016/j.annonc.2019.10.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 29.0] [Reference Citation Analysis]
169 Price TJ, Tang M, Gibbs P, Haller DG, Peeters M, Arnold D, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M, Shapiro J. Targeted therapy for metastatic colorectal cancer. Expert Rev Anticancer Ther 2018;18:991-1006. [PMID: 30019590 DOI: 10.1080/14737140.2018.1502664] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
170 Jiang N, Saba NF, Chen ZG. Advances in Targeting HER3 as an Anticancer Therapy. Chemother Res Pract 2012;2012:817304. [PMID: 23198146 DOI: 10.1155/2012/817304] [Cited by in Crossref: 10] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis]
171 Huang S, Li C, Armstrong EA, Peet CR, Saker J, Amler LC, Sliwkowski MX, Harari PM. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res 2013;73:824-33. [PMID: 23172311 DOI: 10.1158/0008-5472.CAN-12-1611] [Cited by in Crossref: 125] [Cited by in F6Publishing: 63] [Article Influence: 12.5] [Reference Citation Analysis]
172 Rivera M, Fichtner I, Wulf-Goldenberg A, Sers C, Merk J, Patone G, Alp KM, Kanashova T, Mertins P, Hoffmann J, Stein U, Walther W. Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine. Neoplasia 2021;23:21-35. [PMID: 33212364 DOI: 10.1016/j.neo.2020.11.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
173 Dienstmann R, Salazar R, Tabernero J. Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer. Am Soc Clin Oncol Educ Book. 2015;: e149-e156. [PMID: 25993166 DOI: 10.14694/edbook_am.2015.35.e149] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
174 Sartore-Bianchi A, Amatu A, Porcu L, Ghezzi S, Lonardi S, Leone F, Bergamo F, Fenocchio E, Martinelli E, Borelli B, Tosi F, Racca P, Valtorta E, Bonoldi E, Martino C, Vaghi C, Marrapese G, Ciardiello F, Zagonel V, Bardelli A, Trusolino L, Torri V, Marsoni S, Siena S. HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. Oncologist. 2019;24:1395-1402. [PMID: 30952821 DOI: 10.1634/theoncologist.2018-0785] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 10.7] [Reference Citation Analysis]
175 de Farias CB, Heinen TE, dos Santos RP, Abujamra AL, Schwartsmann G, Roesler R. BDNF/TrkB signaling protects HT-29 human colon cancer cells from EGFR inhibition. Biochem Biophys Res Commun. 2012;425:328-332. [PMID: 22842573 DOI: 10.1016/j.bbrc.2012.07.091] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
176 Obaya AA, Mohammed AA, Rashied H, Morsy AM, Osman G, Allam AS, Elsayed AM, Harb OA, Elsayed WSH. Evaluating the value of Amphiregulin, Phosphatase and Tensin Homologue (PTEN) and P21 Expression for Anti-EGFR Treatment in Metastatic Colorectal Carcinoma. Asian Pac J Cancer Prev 2021;22:1025-34. [PMID: 33906293 DOI: 10.31557/APJCP.2021.22.4.1025] [Reference Citation Analysis]
177 Malm M, Frejd FY, Ståhl S, Löfblom J. Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds. MAbs 2016;8:1195-209. [PMID: 27532938 DOI: 10.1080/19420862.2016.1212147] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
178 Parakh S, Gan HK, Parslow AC, Burvenich IJG, Burgess AW, Scott AM. Evolution of anti-HER2 therapies for cancer treatment. Cancer Treat Rev 2017;59:1-21. [PMID: 28715775 DOI: 10.1016/j.ctrv.2017.06.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 10.0] [Reference Citation Analysis]
179 Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21:795-801. [PMID: 26030179 DOI: 10.1038/nm.3870] [Cited by in Crossref: 473] [Cited by in F6Publishing: 424] [Article Influence: 67.6] [Reference Citation Analysis]
180 Birkman EM, Avoranta T, Ålgars A, Korkeila E, Lintunen M, Lahtinen L, Kuopio T, Ristamäki R, Carpén O, Sundström J. EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer. Hum Pathol 2018;82:163-71. [PMID: 30096327 DOI: 10.1016/j.humpath.2018.07.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
181 Tang J, Szwajda A, Shakyawar S, Xu T, Hintsanen P, Wennerberg K, Aittokallio T. Making Sense of Large-Scale Kinase Inhibitor Bioactivity Data Sets: A Comparative and Integrative Analysis. J Chem Inf Model 2014;54:735-43. [DOI: 10.1021/ci400709d] [Cited by in Crossref: 80] [Cited by in F6Publishing: 58] [Article Influence: 10.0] [Reference Citation Analysis]
182 Styczen H, Nagelmeier I, Beissbarth T, Nietert M, Homayounfar K, Sprenger T, Boczek U, Stanek K, Kitz J, Wolff HA, Ghadimi BM, Middel P, Liersch T, Rüschoff J, Conradi LC. HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer. Oncotarget 2015;6:15065-76. [PMID: 25915155 DOI: 10.18632/oncotarget.3527] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
183 Richman SD, Southward K, Chambers P, Cross D, Barrett J, Hemmings G, Taylor M, Wood H, Hutchins G, Foster JM, Oumie A, Spink KG, Brown SR, Jones M, Kerr D, Handley K, Gray R, Seymour M, Quirke P. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016;238:562-570. [PMID: 26690310 DOI: 10.1002/path.4679] [Cited by in Crossref: 95] [Cited by in F6Publishing: 92] [Article Influence: 15.8] [Reference Citation Analysis]
184 Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012;343:342-350. [PMID: 22888144 DOI: 10.1124/jpet.112.197756] [Cited by in Crossref: 544] [Cited by in F6Publishing: 511] [Article Influence: 54.4] [Reference Citation Analysis]
185 Miyamoto Y, Suyama K, Baba H. Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. Int J Mol Sci 2017;18:E752. [PMID: 28368335 DOI: 10.3390/ijms18040752] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
186 Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 2012;12:553-63. [PMID: 22785351 DOI: 10.1038/nrc3309] [Cited by in Crossref: 507] [Cited by in F6Publishing: 459] [Article Influence: 50.7] [Reference Citation Analysis]
187 Jebbink M, de Langen AJ, Boelens MC, Monkhorst K, Smit EF. The force of HER2 - A druggable target in NSCLC? Cancer Treat Rev 2020;86:101996. [PMID: 32135383 DOI: 10.1016/j.ctrv.2020.101996] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
188 Fanotto V, Ongaro E, Rihawi K, Avallone A, Silvestris N, Fornaro L, Vasile E, Antonuzzo L, Leone F, Rosati G. HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. Oncotarget. 2016;7:69060-69074. [PMID: 27542243 DOI: 10.18632/oncotarget.11264] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
189 Vlacich G, Coffey RJ. Resistance to EGFR-targeted therapy: a family affair. Cancer Cell 2011;20:423-5. [PMID: 22014569 DOI: 10.1016/j.ccr.2011.10.006] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 4.7] [Reference Citation Analysis]
190 Qiao J, Liu Z, Fu Y. Adapting conventional cancer treatment for immunotherapy. J Mol Med 2016;94:489-95. [DOI: 10.1007/s00109-016-1393-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
191 Sun Z, Fu YX, Peng H. Targeting tumor cells with antibodies enhances anti-tumor immunity. Biophys Rep 2018;4:243-53. [PMID: 30533489 DOI: 10.1007/s41048-018-0070-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
192 Ebbing EA, Medema JP, Damhofer H, Meijer SL, Krishnadath KK, van Berge Henegouwen MI, Bijlsma MF, van Laarhoven HW. ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3. Oncotarget 2016;7:10243-54. [PMID: 26863569 DOI: 10.18632/oncotarget.7200] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
193 Kanat O, Ertas H, Caner B. Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status. World J Clin Cases 2018; 6(11): 418-425 [PMID: 30294606 DOI: 10.12998/wjcc.v6.i11.418] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
194 Mohan S, Heitzer E, Ulz P, Lafer I, Lax S, Auer M, Pichler M, Gerger A, Eisner F, Hoefler G, Bauernhofer T, Geigl JB, Speicher MR. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet 2014;10:e1004271. [PMID: 24676216 DOI: 10.1371/journal.pgen.1004271] [Cited by in Crossref: 129] [Cited by in F6Publishing: 109] [Article Influence: 16.1] [Reference Citation Analysis]
195 Sartore-Bianchi A, Siena S. Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer. Handb Exp Pharmacol 2018;249:145-59. [PMID: 28382467 DOI: 10.1007/164_2017_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
196 Rabinowits G, Haddad RI. Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. Oral Oncol 2012;48:1085-9. [PMID: 22840785 DOI: 10.1016/j.oraloncology.2012.06.016] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 5.1] [Reference Citation Analysis]
197 Temraz S, Mukherji D, Alameddine R, Shamseddine A. Methods of overcoming treatment resistance in colorectal cancer. Crit Rev Oncol Hematol 2014;89:217-30. [PMID: 24075059 DOI: 10.1016/j.critrevonc.2013.08.015] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
198 Yin P, Cui S, Liao X, Yao X. Galectin‑3 blockade suppresses the growth of cetuximab‑resistant human oral squamous cell carcinoma. Mol Med Rep 2021;24:685. [PMID: 34328195 DOI: 10.3892/mmr.2021.12325] [Reference Citation Analysis]
199 Khan MI, Czarnecka AM, Lewicki S, Helbrecht I, Brodaczewska K, Koch I, Zdanowski R, Król M, Szczylik C. Comparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer Cells. PLoS One 2016;11:e0165718. [PMID: 27812180 DOI: 10.1371/journal.pone.0165718] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
200 Oxnard GR, Schwartz LH. Response Phenotype As a Predictive Biomarker to Guide Treatment With Targeted Therapies. JCO 2013;31:3739-41. [DOI: 10.1200/jco.2013.51.8365] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
201 Gogoi D, Baruah VJ, Chaliha AK, Kakoti BB, Sarma D, Buragohain AK. 3D pharmacophore-based virtual screening, docking and density functional theory approach towards the discovery of novel human epidermal growth factor receptor-2 (HER2) inhibitors. J Theor Biol 2016;411:68-80. [PMID: 27693363 DOI: 10.1016/j.jtbi.2016.09.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
202 Hrustanovic G, Lee BJ, Bivona TG. Mechanisms of resistance to EGFR targeted therapies. Cancer Biol Ther 2013;14:304-14. [PMID: 23358468 DOI: 10.4161/cbt.23627] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
203 Yonesaka K, Hirotani K, von Pawel J, Dediu M, Chen S, Copigneaux C, Nakagawa K. Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer. Lung Cancer 2017;105:1-6. [PMID: 28236978 DOI: 10.1016/j.lungcan.2016.12.018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
204 Lin L, Bivona TG. Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients. Chemother Res Pract 2012;2012:817297. [PMID: 22970367 DOI: 10.1155/2012/817297] [Cited by in Crossref: 11] [Cited by in F6Publishing: 43] [Article Influence: 1.1] [Reference Citation Analysis]
205 Hu L, Liang S, Chen H, Lv T, Wu J, Chen D, Wu M, Sun S, Zhang H, You H, Ji H, Zhang Y, Bergholz J, Xiao ZJ. ΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis. Proc Natl Acad Sci U S A 2017;114:E3964-73. [PMID: 28468801 DOI: 10.1073/pnas.1617816114] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
206 Yonesaka K, Iwama E, Hayashi H, Suzuki S, Kato R, Watanabe S, Takahama T, Tanizaki J, Tanaka K, Takeda M, Sakai K, Azuma K, Chiba Y, Atagi S, Nishio K, Okamoto I, Nakagawa K. Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors. Sci Rep 2019;9:19501. [PMID: 31862929 DOI: 10.1038/s41598-019-55939-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
207 Guarini C, Grassi T, Pezzicoli G, Porta C. Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer. Int J Mol Sci 2021;22:6813. [PMID: 34202896 DOI: 10.3390/ijms22136813] [Reference Citation Analysis]
208 Logue JS, Morrison DK. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev. 2012;26:641-650. [PMID: 22474259 DOI: 10.1101/gad.186965.112] [Cited by in Crossref: 183] [Cited by in F6Publishing: 154] [Article Influence: 18.3] [Reference Citation Analysis]
209 Tiash S, Kamaruzman NIB, Chowdhury EH. Carbonate apatite nanoparticles carry siRNA(s) targeting growth factor receptor genes egfr1 and erbb2 to regress mouse breast tumor. Drug Delivery 2017;24:1721-30. [DOI: 10.1080/10717544.2017.1396385] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
210 Maisel SA, Broka D, Atwell B, Bunch T, Kupp R, Singh SK, Mehta S, Schroeder J. Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer. J Transl Med 2019;17:201. [PMID: 31215437 DOI: 10.1186/s12967-019-1939-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
211 Cen S, Liu Z, Pan H, Han W. Clinicopathologic features and treatment advances in cancers with HER2 alterations. Biochim Biophys Acta Rev Cancer 2021;1876:188605. [PMID: 34358635 DOI: 10.1016/j.bbcan.2021.188605] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
212 Fakih M. Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine. Future Oncology 2013;9:551-60. [DOI: 10.2217/fon.12.204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
213 Lee YS, Johnson DE, Grandis JR. An update: emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs 2018;23:283-99. [PMID: 30376740 DOI: 10.1080/14728214.2018.1543400] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
214 Zhang H, Liu R, Yan C, Liu L, Tong Z, Jiang W, Yao M, Fang W, Chen Z. Advantage of Next-Generation Sequencing in Dynamic Monitoring of Circulating Tumor DNA over Droplet Digital PCR in Cetuximab Treated Colorectal Cancer Patients. Transl Oncol 2019;12:426-31. [PMID: 30562681 DOI: 10.1016/j.tranon.2018.11.015] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
215 Wang H, Stoecklein NH, Lin PP, Gires O. Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion. Oncotarget 2017;8:1884-912. [PMID: 27683128 DOI: 10.18632/oncotarget.12242] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 10.3] [Reference Citation Analysis]
216 Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486:537-540. [PMID: 22722843 DOI: 10.1038/nature11219] [Cited by in Crossref: 1154] [Cited by in F6Publishing: 1025] [Article Influence: 115.4] [Reference Citation Analysis]
217 Davidson MA, Shanks EJ. 3q26-29 Amplification in head and neck squamous cell carcinoma: a review of established and prospective oncogenes. FEBS J 2017;284:2705-31. [PMID: 28317270 DOI: 10.1111/febs.14061] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
218 Zscheppang K, Kurth I, Wachtel N, Dubrovska A, Kunz-Schughart LA, Cordes N. Efficacy of Beta1 Integrin and EGFR Targeting in Sphere-Forming Human Head and Neck Cancer Cells. J Cancer 2016;7:736-45. [PMID: 27076856 DOI: 10.7150/jca.14232] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
219 Chen C, Di Bartolomeo M, Corallo S, Strickler JH, Goyal L. Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come. Am Soc Clin Oncol Educ Book 2020;40:161-73. [PMID: 32421451 DOI: 10.1200/EDBK_280871] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
220 Lyu H, Han A, Polsdofer E, Liu S, Liu B. Understanding the biology of HER3 receptor as a therapeutic target in human cancer. Acta Pharm Sin B 2018;8:503-10. [PMID: 30109175 DOI: 10.1016/j.apsb.2018.05.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
221 Nowak JA. HER2 in Colorectal Carcinoma: Are We There yet? Surg Pathol Clin 2020;13:485-502. [PMID: 32773196 DOI: 10.1016/j.path.2020.05.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
222 Lyu J, Song H, Tian Z, Miao Y, Ren G, Guo W. Predictive value of pAKT/PTEN expression in oral squamous cell carcinoma treated with cetuximab-based chemotherapy. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 2016;121:67-72. [DOI: 10.1016/j.oooo.2015.09.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
223 Sobani ZA, Sawant A, Jafri M, Correa AK, Sahin IH. Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer. World J Clin Oncol 2016; 7(5): 340-351 [PMID: 27777877 DOI: 10.5306/wjco.v7.i5.340] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
224 Price KA, Cohen EE. Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN). Oral Oncol 2015;51:399-408. [PMID: 25725588 DOI: 10.1016/j.oraloncology.2015.01.018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
225 Zhao B, Wang L, Qiu H, Zhang M, Sun L, Peng P, Yu Q, Yuan X. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget 2017;8:3980-4000. [PMID: 28002810 DOI: 10.18632/oncotarget.14012] [Cited by in Crossref: 121] [Cited by in F6Publishing: 115] [Article Influence: 30.3] [Reference Citation Analysis]
226 Liu X, Liu S, Lyu H, Riker AI, Zhang Y, Liu B. Development of Effective Therapeutics Targeting HER3 for Cancer Treatment. Biol Proced Online 2019;21:5. [PMID: 30930695 DOI: 10.1186/s12575-019-0093-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
227 Tsuchida N, Murugan AK, Grieco M. Kirsten Ras* oncogene: significance of its discovery in human cancer research. Oncotarget 2016;7:46717-33. [PMID: 27102293 DOI: 10.18632/oncotarget.8773] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
228 Wang G, He Y, Sun Y, Wang W, Qian X, Yu X, Pan Y. Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer. Clin Transl Oncol 2020;22:813-22. [PMID: 31587152 DOI: 10.1007/s12094-019-02213-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
229 Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Sineshchekova O, Saxena P, Sutton CR, Chen D, Chen Y, Wang H, Liang J, Das R, Mosher R, Gu J, Huang A, Haubst N, Zehetmeier C, Haberl M, Elis W, Kunz C, Heidt AB, Herlihy K, Murtie J, Schuller A, Arteaga CL, Sellers WR, Ettenberg SA. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res 2013;73:6024-35. [PMID: 23928993 DOI: 10.1158/0008-5472.CAN-13-1198] [Cited by in Crossref: 89] [Cited by in F6Publishing: 55] [Article Influence: 9.9] [Reference Citation Analysis]
230 Khanna V, Panyam J, Griffith TS. Exploiting antibody biology for the treatment of cancer. Immunotherapy 2020;12:255-67. [DOI: 10.2217/imt-2019-0118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
231 Ghasabi M, Mansoori B, Mohammadi A, Duijf PH, Shomali N, Shirafkan N, Mokhtarzadeh A, Baradaran B. MicroRNAs in cancer drug resistance: Basic evidence and clinical applications. J Cell Physiol 2019;234:2152-68. [PMID: 30146724 DOI: 10.1002/jcp.26810] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
232 Luo M, Yang X, Chen HN, Nice EC, Huang C. Drug resistance in colorectal cancer: An epigenetic overview. Biochim Biophys Acta Rev Cancer 2021;1876:188623. [PMID: 34481016 DOI: 10.1016/j.bbcan.2021.188623] [Reference Citation Analysis]
233 Gamba S, Camaj P, Heinemann V, Laubender RP, Wang Y, Zhao Y, Stintzing S, Giessen C, Boeck S, Haertl C, Bruns CJ, Modest DP. Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib. Anticancer Drugs 2015;26:371-8. [PMID: 25514114 DOI: 10.1097/CAD.0000000000000196] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
234 Beaubier N, Bontrager M, Huether R, Igartua C, Lau D, Tell R, Bobe AM, Bush S, Chang AL, Hoskinson DC, Khan AA, Kudalkar E, Leibowitz BD, Lozachmeur A, Michuda J, Parsons J, Perera JF, Salahudeen A, Shah KP, Taxter T, Zhu W, White KP. Integrated genomic profiling expands clinical options for patients with cancer. Nat Biotechnol 2019;37:1351-60. [PMID: 31570899 DOI: 10.1038/s41587-019-0259-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 12.3] [Reference Citation Analysis]
235 Pollock NI, Grandis JR. HER2 as a therapeutic target in head and neck squamous cell carcinoma. Clin Cancer Res 2015;21:526-33. [PMID: 25424855 DOI: 10.1158/1078-0432.CCR-14-1432] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
236 Tashiro T, Okuyama H, Endo H, Kawada K, Ashida Y, Ohue M, Sakai Y, Inoue M. In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer. PLoS One 2017;12:e0174151. [PMID: 28301591 DOI: 10.1371/journal.pone.0174151] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
237 Pereira PM, Abma L, Henry KE, Lewis JS. Imaging of human epidermal growth factor receptors for patient selection and response monitoring – From PET imaging and beyond. Cancer Letters 2018;419:139-51. [DOI: 10.1016/j.canlet.2018.01.052] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
238 Perez R, Crombet T, de Leon J, Moreno E. A view on EGFR-targeted therapies from the oncogene-addiction perspective. Front Pharmacol 2013;4:53. [PMID: 23637683 DOI: 10.3389/fphar.2013.00053] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
239 Silvestris N, Vincenzi B, Brunetti AE, Loupakis F, Dell’Aquila E, Russo A, Scartozzi M, Giampieri R, Cascinu S, Lorusso V. Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. Pharmacogenomics. 2014;15:1701-1715. [PMID: 25410895 DOI: 10.2217/pgs.14.124] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
240 Wang X, Beitler JJ, Wang H, Lee MJ, Huang W, Koenig L, Nannapaneni S, Amin AR, Bonner M, Shin HJ, Chen ZG, Arbiser JL, Shin DM. Honokiol enhances paclitaxel efficacy in multi-drug resistant human cancer model through the induction of apoptosis. PLoS One 2014;9:e86369. [PMID: 24586249 DOI: 10.1371/journal.pone.0086369] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
241 Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, Zagonel V, Leone F, Depetris I, Martinelli E, Troiani T, Ciardiello F, Racca P, Bertotti A, Siravegna G, Torri V, Amatu A, Ghezzi S, Marrapese G, Palmeri L, Valtorta E, Cassingena A, Lauricella C, Vanzulli A, Regge D, Veronese S, Comoglio PM, Bardelli A, Marsoni S, Siena S. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738-746. [PMID: 27108243 DOI: 10.1016/s1470-2045(16)00150-9] [Cited by in Crossref: 428] [Cited by in F6Publishing: 235] [Article Influence: 71.3] [Reference Citation Analysis]
242 Mehta R. The Role of HER2 Testing in Advanced Colorectal Cancer. Curr Colorectal Cancer Rep 2018;14:184-91. [DOI: 10.1007/s11888-018-0417-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
243 Barry GS, Cheang MC, Chang HL, Kennecke HF. Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC). Oncotarget 2016;7:18953-64. [PMID: 26980732 DOI: 10.18632/oncotarget.8006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
244 Taylor TE, Furnari FB, Cavenee WK. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets 2012;12:197-209. [PMID: 22268382 DOI: 10.2174/156800912799277557] [Cited by in Crossref: 143] [Cited by in F6Publishing: 135] [Article Influence: 14.3] [Reference Citation Analysis]
245 El Bali M, Bakkach J, Bennani Mechita M. Colorectal Cancer: From Genetic Landscape to Targeted Therapy. J Oncol 2021;2021:9918116. [PMID: 34326875 DOI: 10.1155/2021/9918116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
246 Jia R, Zhao H, Wang S. Neuregulin Signaling in the Tumor Microenvironment. Adv Exp Med Biol 2021;1270:1-29. [PMID: 33123990 DOI: 10.1007/978-3-030-47189-7_1] [Reference Citation Analysis]
247 Pectasides E, Bass AJ. ERBB2 emerges as a new target for colorectal cancer. Cancer Discov 2015;5:799-801. [PMID: 26243861 DOI: 10.1158/2159-8290.CD-15-0730] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
248 Clark PA, Iida M, Treisman DM, Kalluri H, Ezhilan S, Zorniak M, Wheeler DL, Kuo JS. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition. Neoplasia 2012;14:420-8. [PMID: 22745588 DOI: 10.1596/neo.12432] [Cited by in Crossref: 93] [Cited by in F6Publishing: 90] [Article Influence: 9.3] [Reference Citation Analysis]
249 Jiang J, Ma T, Xi W, Yang C, Wu J, Zhou C, Wang N, Zhu Z, Zhang J. Pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy. Cancer Manag Res 2019;11:8657-68. [PMID: 31576170 DOI: 10.2147/CMAR.S211089] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
250 Khan K, Valeri N, Dearman C, Rao S, Watkins D, Starling N, Chau I, Cunningham D. Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution. Crit Rev Oncol Hematol. 2019;143:153-163. [PMID: 31678702 DOI: 10.1016/j.critrevonc.2019.09.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
251 Yonesaka K, Takegawa N, Satoh T, Ueda H, Yoshida T, Takeda M, Shimizu T, Chiba Y, Okamoto I, Nishio K, Tamura T, Nakagawa K. Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer. PLoS One 2015;10:e0143132. [PMID: 26569500 DOI: 10.1371/journal.pone.0143132] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
252 Yang L, Li Y, Bhattacharya A, Zhang Y. Dual inhibition of ErbB1 and ErbB2 in cancer by recombinant human prolidase mutant hPEPD-G278D. Oncotarget 2016;7:42340-52. [PMID: 27286447 DOI: 10.18632/oncotarget.9851] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
253 Yonesaka K, Kudo K, Nishida S, Takahama T, Iwasa T, Yoshida T, Tanaka K, Takeda M, Kaneda H, Okamoto I, Nishio K, Nakagawa K. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer. Oncotarget 2015;6:33602-11. [PMID: 26418897 DOI: 10.18632/oncotarget.5286] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
254 Jang B, Kwon H, Katila P, Lee SJ, Lee H. Dual delivery of biological therapeutics for multimodal and synergistic cancer therapies. Advanced Drug Delivery Reviews 2016;98:113-33. [DOI: 10.1016/j.addr.2015.10.023] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 9.7] [Reference Citation Analysis]
255 Belli V, Matrone N, Napolitano S, Migliardi G, Cottino F, Bertotti A, Trusolino L, Martinelli E, Morgillo F, Ciardiello D, De Falco V, Giunta EF, Bracale U, Ciardiello F, Troiani T. Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. J Exp Clin Cancer Res 2019;38:236. [PMID: 31164152 DOI: 10.1186/s13046-019-1230-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
256 Takegawa N, Tsurutani J, Kawakami H, Yonesaka K, Kato R, Haratani K, Hayashi H, Takeda M, Nonagase Y, Maenishi O, Nakagawa K. [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification. Int J Cancer 2019;145:3414-24. [PMID: 31087550 DOI: 10.1002/ijc.32408] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
257 Sakai K, Takeda H, Nishijima N, Orito E, Joko K, Uchida Y, Izumi N, Nishio K, Osaki Y. Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib. Oncotarget 2015;6:21636-44. [PMID: 26046304 DOI: 10.18632/oncotarget.4270] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
258 Patil N, Abba M, Allgayer H. Cetuximab and biomarkers in non-small-cell lung carcinoma. Biologics 2012;6:221-31. [PMID: 22904614 DOI: 10.2147/BTT.S24217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.1] [Reference Citation Analysis]
259 Pan T, Sun J, Hu J, Hu Y, Zhou J, Chen Z, Xu D, Xu W, Zheng S, Zhang S. Cytohesins/ARNO: the function in colorectal cancer cells. PLoS One 2014;9:e90997. [PMID: 24618737 DOI: 10.1371/journal.pone.0090997] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
260 Takahashi N, Iwasa S, Taniguchi H, Sasaki Y, Shoji H, Honma Y, Takashima A, Okita N, Kato K, Hamaguchi T, Shimada Y, Yamada Y. Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies. Br J Cancer 2016;114:1003-11. [PMID: 27002940 DOI: 10.1038/bjc.2016.74] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
261 Brijwani N, Jain M, Dhandapani M, Zahed F, Mukhopadhyay P, Biswas M, Khatri D, Radhakrishna VD, Majumder B, Radhakrishnan P, Thiyagarajan S. Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2. Sci Rep 2017;7:1502. [PMID: 28473715 DOI: 10.1038/s41598-017-01566-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
262 Dogan M, Guresci S, Acikgoz Y, Ergun Y, Kos FT, Bozdogan O, Bal O. Is there any correlation among MKK4 (mitogen-activated protein kinase kinase 4) expression, clinicopathological features, and KRAS/NRAS mutation in colorectal cancer. Expert Rev Mol Diagn 2020;20:851-9. [PMID: 32552144 DOI: 10.1080/14737159.2020.1784728] [Reference Citation Analysis]
263 Hu S, Dai H, Li T, Tang Y, Fu W, Yuan Q, Wang F, Lv G, Lv Y, Fan X, Zhang S, Jin R, Shen Y, Lin F, Ye X, Ding M, Yang Y, Lei C. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. Cancer Letters 2016;382:32-43. [DOI: 10.1016/j.canlet.2016.08.022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
264 Pabla B, Bissonnette M, Konda VJ. Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention. World J Clin Oncol 2015; 6(5): 133-141 [PMID: 26468449 DOI: 10.5306/wjco.v6.i5.133] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 45] [Article Influence: 7.1] [Reference Citation Analysis]
265 Qiu MZ, He CY, Yang XH, Yang LQ, Lin JZ, Zhou DL, Long YK, Guan WL, Jin Y, Li YH, Wang FH, Yang DJ, Xu RH. Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma. Oncologist 2021;26:e1161-70. [PMID: 33844372 DOI: 10.1002/onco.13786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
266 Antoniotti C, Pietrantonio F, Corallo S, De Braud F, Falcone A, Cremolini C. Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality. JCO Precision Oncology 2019. [DOI: 10.1200/po.18.00397] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
267 Carragher NO, Unciti-Broceta A, Cameron DA. Advancing cancer drug discovery towards more agile development of targeted combination therapies. Future Med Chem 2012;4:87-105. [PMID: 22168166 DOI: 10.4155/fmc.11.169] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
268 Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013;3:658-673. [PMID: 23729478 DOI: 10.1158/2159-8290.cd-12-0558] [Cited by in Crossref: 421] [Cited by in F6Publishing: 249] [Article Influence: 46.8] [Reference Citation Analysis]
269 Cleary JM, McRee AJ, Shapiro GI, Tolaney SM, O'Neil BH, Kearns JD, Mathews S, Nering R, MacBeath G, Czibere A, Sharma S, Korn WM. A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan. Invest New Drugs 2017;35:68-78. [PMID: 27853996 DOI: 10.1007/s10637-016-0399-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
270 Peterson TA, Gauran IIM, Park J, Park D, Kann MG. Oncodomains: A protein domain-centric framework for analyzing rare variants in tumor samples. PLoS Comput Biol 2017;13:e1005428. [PMID: 28426665 DOI: 10.1371/journal.pcbi.1005428] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
271 Kasagi Y, Oki E, Ando K, Kimura Y, Ikegami T, Saeki H, Morita M, Kusumoto T, Maehara Y. A case of panitumumab-responsive metastatic rectal cancer initially refractory to cetuximab. Case Rep Oncol 2013;6:382-6. [PMID: 23904849 DOI: 10.1159/000353781] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
272 Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer 2018;17:53. [PMID: 29455669 DOI: 10.1186/s12943-018-0793-1] [Cited by in Crossref: 76] [Cited by in F6Publishing: 83] [Article Influence: 19.0] [Reference Citation Analysis]
273 Shitara K, Yonesaka K, Denda T, Yamazaki K, Moriwaki T, Tsuda M, Takano T, Okuda H, Nishina T, Sakai K, Nishio K, Tokunaga S, Yamanaka T, Boku N, Hyodo I, Muro K. Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. Cancer Sci. 2016;107:1843-1850. [PMID: 27712015 DOI: 10.1111/cas.13098] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
274 Troiani T, Zappavigna S, Martinelli E, Addeo SR, Stiuso P, Ciardiello F, Caraglia M. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. Expert Opin Biol Ther. 2013;13:241-255. [PMID: 23281932 DOI: 10.1517/14712598.2012.756469] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
275 Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. 2015;526:263-267. [PMID: 26416732 DOI: 10.1038/nature14969] [Cited by in Crossref: 265] [Cited by in F6Publishing: 247] [Article Influence: 37.9] [Reference Citation Analysis]
276 Bray SM, Lee J, Kim ST, Hur JY, Ebert PJ, Calley JN, Wulur IH, Gopalappa T, Wong SS, Qian HR, Ting JC, Liu J, Willard MD, Novosiadly RD, Park YS, Park JO, Lim HY, Kang WK, Aggarwal A, Kim HC, Reinhard C. Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients. Sci Rep 2019;9:15365. [PMID: 31653970 DOI: 10.1038/s41598-019-51981-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
277 Jain S, Kumar S. Cancer immunotherapy: dawn of the death of cancer? Int Rev Immunol 2020;:1-18. [PMID: 32530336 DOI: 10.1080/08830185.2020.1775827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
278 Chariou PL, Lee KL, Wen AM, Gulati NM, Stewart PL, Steinmetz NF. Detection and imaging of aggressive cancer cells using an epidermal growth factor receptor (EGFR)-targeted filamentous plant virus-based nanoparticle. Bioconjug Chem 2015;26:262-9. [PMID: 25611133 DOI: 10.1021/bc500545z] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
279 Pan T, Sun J, Zhou J, Fu Z, Hu Y, Zheng S, Zhang S. Function and mode of action of cytohesins in the epidermal growth factor pathway in colorectal cancer cells. Oncol Lett 2013;5:521-6. [PMID: 23420529 DOI: 10.3892/ol.2012.1064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
280 Takegawa N, Yonesaka K, Sakai K, Ueda H, Watanabe S, Nonagase Y, Okuno T, Takeda M, Maenishi O, Tsurutani J, Satoh T, Okamoto I, Nishio K, Tamura T, Nakagawa K. HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer. Oncotarget 2016;7:3453-60. [PMID: 26657506 DOI: 10.18632/oncotarget.6498] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
281 Chen KH, Shao YY, Chen HM, Lin YL, Lin ZZ, Lai MS, Cheng AL, Yeh KH. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study. BMC Cancer. 2016;16:327. [PMID: 27221731 DOI: 10.1186/s12885-016-2358-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
282 Novoplansky O, Fury M, Prasad M, Yegodayev K, Zorea J, Cohen L, Pelossof R, Cohen L, Katabi N, Cecchi F, Joshua BZ, Popovtzer A, Baselga J, Scaltriti M, Elkabets M. MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer. Int J Cancer 2019;145:748-62. [PMID: 30694565 DOI: 10.1002/ijc.32170] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
283 Kavuri SM, Jain N, Galimi F, Cottino F, Leto SM, Migliardi G, Searleman AC, Shen W, Monsey J, Trusolino L. HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov. 2015;5:832-841. [PMID: 26243863 DOI: 10.1158/2159-8290.cd-14-1211] [Cited by in Crossref: 150] [Cited by in F6Publishing: 97] [Article Influence: 25.0] [Reference Citation Analysis]
284 Ebelt ND, Manuel ER. Utilizing Salmonella to treat solid malignancies. J Surg Oncol 2017;116:75-82. [PMID: 28420039 DOI: 10.1002/jso.24644] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
285 Deeken JF, Wang H, Subramaniam D, He AR, Hwang J, Marshall JL, Urso CE, Wang Y, Ramos C, Steadman K, Pishvaian MJ. A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies. Cancer. 2015;121:1645-1653. [PMID: 25641763 DOI: 10.1002/cncr.29224] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
286 Mishra R, Patel H, Alanazi S, Yuan L, Garrett JT. HER3 signaling and targeted therapy in cancer. Oncol Rev 2018;12:355. [PMID: 30057690 DOI: 10.4081/oncol.2018.355] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 10.8] [Reference Citation Analysis]
287 Liu J, Hu J, Cheng L, Ren W, Yang M, Liu B, Xie L, Qian X. Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS. Onco Targets Ther 2016;9:557-65. [PMID: 26869800 DOI: 10.2147/OTT.S86966] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
288 Williams JP, Kim I, Ito E, Shi W, Yue S, Siu LL, Waldron J, O'Sullivan B, Yip KW, Liu FF. Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma. PLoS One 2014;9:e98557. [PMID: 24853121 DOI: 10.1371/journal.pone.0098557] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
289 Lowery FJ, Yu D. Growth factor signaling in metastasis: current understanding and future opportunities. Cancer Metastasis Rev 2012;31:479-91. [DOI: 10.1007/s10555-012-9380-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
290 Jacobs SA, Lee JJ, George TJ, Wade JL 3rd, Stella PJ, Wang D, Sama AR, Piette F, Pogue-Geile KL, Kim RS, Gavin PG, Lipchik C, Feng H, Wang Y, Finnigan M, Kiesel BF, Beumer JH, Wolmark N, Lucas PC, Allegra CJ, Srinivasan A. Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study. Clin Cancer Res 2021;27:1612-22. [PMID: 33203645 DOI: 10.1158/1078-0432.CCR-20-1831] [Reference Citation Analysis]
291 Martinelli E, Morgillo F, Troiani T, Ciardiello F. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. Cancer Treat Rev. 2017;53:61-69. [PMID: 28073102 DOI: 10.1016/j.ctrv.2016.12.001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 60] [Article Influence: 9.2] [Reference Citation Analysis]
292 Konieczkowski DJ, Johannessen CM, Garraway LA. A Convergence-Based Framework for Cancer Drug Resistance. Cancer Cell 2018;33:801-15. [PMID: 29763622 DOI: 10.1016/j.ccell.2018.03.025] [Cited by in Crossref: 93] [Cited by in F6Publishing: 80] [Article Influence: 31.0] [Reference Citation Analysis]
293 Zhu JQ, Ou WB. Therapeutic targets in gastrointestinal stromal tumors. World J Transl Med 2015; 4(1): 25-37 [DOI: 10.5528/wjtm.v4.i1.25] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
294 Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Degese MS, Vitale-Cross L, Chen Q, Gutkind JS. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. J Natl Cancer Inst 2014;106:dju215. [PMID: 25099740 DOI: 10.1093/jnci/dju215] [Cited by in Crossref: 64] [Cited by in F6Publishing: 73] [Article Influence: 8.0] [Reference Citation Analysis]
295 Temraz S, Mukherji D, Shamseddine A. Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance. Crit Rev Oncol Hematol. 2016;101:151-157. [PMID: 27017409 DOI: 10.1016/j.critrevonc.2016.03.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
296 Asić K. Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies. Critical Reviews in Oncology/Hematology 2016;97:178-96. [DOI: 10.1016/j.critrevonc.2015.08.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
297 Ou GY, Lin WW, Zhao WJ. Neuregulins in Neurodegenerative Diseases. Front Aging Neurosci 2021;13:662474. [PMID: 33897409 DOI: 10.3389/fnagi.2021.662474] [Reference Citation Analysis]
298 Parakh S, King D, Gan HK, Scott AM. Current Development of Monoclonal Antibodies in Cancer Therapy. Recent Results Cancer Res 2020;214:1-70. [PMID: 31473848 DOI: 10.1007/978-3-030-23765-3_1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
299 Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer 2013;13:663-73. [DOI: 10.1038/nrc3559] [Cited by in Crossref: 244] [Cited by in F6Publishing: 218] [Article Influence: 27.1] [Reference Citation Analysis]
300 Troiani T, Martinelli E, Morgillo F, Capasso A, Nappi A, Sforza V, Ciardiello F. Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab? Ther Adv Med Oncol 2013;5:51-72. [PMID: 23323147 DOI: 10.1177/1758834012462462] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
301 Sousa N, Sousa O, Santos LL, Henrique R, Teixeira MR, Dinis-Ribeiro M, Teixeira-Pinto A. Lapatinib-capecitabine versus capecitabine alone as radiosensitizers in RAS wild-type resectable rectal cancer, an adaptive randomized phase II trial (LaRRC trial): study protocol for a randomized controlled trial. Trials 2016;17:459. [PMID: 27655166 DOI: 10.1186/s13063-016-1583-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
302 De Mattia E, Cecchin E, Toffoli G. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. Drug Resistance Updates 2015;20:39-70. [DOI: 10.1016/j.drup.2015.05.003] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
303 Conradi LC, Spitzner M, Metzger AL, Kisly M, Middel P, Bohnenberger H, Gaedcke J, Ghadimi MB, Liersch T, Rüschoff J, Beißbarth T, König A, Grade M. Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer. BMC Cancer 2019;19:880. [PMID: 31488078 DOI: 10.1186/s12885-019-6051-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
304 Hou H, Liu D, Zhang C, Jiang Y, Lu G, Zhou N, Yang X, Zhang X, Li Z, Zhu H, Qian Z, Zhang X. Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine. Oncotarget 2017;8:105072-80. [PMID: 29285234 DOI: 10.18632/oncotarget.21349] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
305 Haikala HM, Jänne PA. Thirty Years of HER3: From Basic Biology to Therapeutic Interventions. Clin Cancer Res 2021;27:3528-39. [PMID: 33608318 DOI: 10.1158/1078-0432.CCR-20-4465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
306 Martini G, Troiani T, Cardone C, Vitiello P, Sforza V, Ciardiello D, Napolitano S, Della Corte CM, Morgillo F, Raucci A, Cuomo A, Selvaggi F, Ciardiello F, Martinelli E. Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. World J Gastroenterol 2017; 23(26): 4675-4688 [PMID: 28765689 DOI: 10.3748/wjg.v23.i26.4675] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 59] [Article Influence: 11.4] [Reference Citation Analysis]
307 Onsum MD, Geretti E, Paragas V, Kudla AJ, Moulis SP, Luus L, Wickham TJ, McDonagh CF, MacBeath G, Hendriks BS. Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients. Am J Pathol 2013;183:1446-60. [PMID: 24035511 DOI: 10.1016/j.ajpath.2013.07.015] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
308 Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532-536. [PMID: 22722830 DOI: 10.1038/nature11156] [Cited by in Crossref: 1174] [Cited by in F6Publishing: 1051] [Article Influence: 117.4] [Reference Citation Analysis]
309 Doyle HA, Koski RA, Bonafé N, Bruck RA, Tagliatela SM, Gee RJ, Mamula MJ. Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3. Cancer Immunol Immunother 2018;67:1559-69. [PMID: 30056598 DOI: 10.1007/s00262-018-2218-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
310 Ortiz-Cuaran S, Bouaoud J, Karabajakian A, Fayette J, Saintigny P. Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers. Front Oncol 2021;11:614332. [PMID: 33718169 DOI: 10.3389/fonc.2021.614332] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
311 Chung YC, Chiu HH, Wei WC, Chang KJ, Chao WT. Application of trastuzumab emtansine in HER-2-positive and KRAS/BRAF-mutated colon cancer cells. Eur J Clin Invest 2020;:e13255. [PMID: 32350854 DOI: 10.1111/eci.13255] [Reference Citation Analysis]
312 De Pauw I, Wouters A, Van den Bossche J, Peeters M, Pauwels P, Deschoolmeester V, Vermorken JB, Lardon F. Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer. Pharmacol Ther 2016;166:71-83. [PMID: 27373506 DOI: 10.1016/j.pharmthera.2016.06.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
313 Abdayem P, Planchard D. Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer. Eur Respir Rev 2021;30:200294. [PMID: 34289984 DOI: 10.1183/16000617.0294-2020] [Reference Citation Analysis]
314 Sarmento-Ribeiro AB, Scorilas A, Gonçalves AC, Efferth T, Trougakos IP. The emergence of drug resistance to targeted cancer therapies: Clinical evidence. Drug Resist Updat 2019;47:100646. [PMID: 31733611 DOI: 10.1016/j.drup.2019.100646] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
315 Shivinsky A, Bronshtein T, Haber T, Machluf M. The effect of AZD2171- or sTRAIL/Apo2L-loaded polylactic-co-glycolic acid microspheres on a subcutaneous glioblastoma model. Biomed Microdevices 2015;17. [DOI: 10.1007/s10544-015-9969-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
316 Atreya CE, Yaeger R, Chu E. Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches. Am Soc Clin Oncol Educ Book 2017;37:246-56. [PMID: 28561718 DOI: 10.1200/EDBK_175679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 0.2] [Reference Citation Analysis]
317 Du Z, Liu X, Chen T, Gao W, Wu Z, Hu Z, Wei D, Gao C, Li Q. Targeting a Sirt5-Positive Subpopulation Overcomes Multidrug Resistance in Wild-Type Kras Colorectal Carcinomas. Cell Rep 2018;22:2677-89. [PMID: 29514096 DOI: 10.1016/j.celrep.2018.02.037] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
318 Lopez-Haber C, Barrio-Real L, Casado-Medrano V, Kazanietz MG. Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and Breast Cancer Cell Motility via Hypoxia-Inducible Factor 1α. Mol Cell Biol 2016;36:2011-26. [PMID: 27185877 DOI: 10.1128/MCB.00180-16] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
319 La Salvia A, Lopez-Gomez V, Garcia-Carbonero R. HER2-targeted therapy: an emerging strategy in advanced colorectal cancer. Expert Opin Investig Drugs 2019;28:29-38. [PMID: 30513002 DOI: 10.1080/13543784.2019.1555583] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
320 Martin V, Cappuzzo F, Mazzucchelli L, Frattini M. HER2 in solid tumors: more than 10 years under the microscope; where are we now? Future Oncol. 2014;10:1469-1486. [PMID: 25052756 DOI: 10.2217/fon.14.19] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
321 Sawada K, Nakamura Y, Yamanaka T, Kuboki Y, Yamaguchi D, Yuki S, Yoshino T, Komatsu Y, Sakamoto N, Okamoto W, Fujii S. Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer 2018;17:198-205. [PMID: 29866615 DOI: 10.1016/j.clcc.2018.05.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
322 Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 2014;14:535-46. [PMID: 25056707 DOI: 10.1038/nrc3775] [Cited by in Crossref: 737] [Cited by in F6Publishing: 759] [Article Influence: 92.1] [Reference Citation Analysis]
323 Jin WJ, Erbe AK, Schwarz CN, Jaquish AA, Anderson BR, Sriramaneni RN, Jagodinsky JC, Bates AM, Clark PA, Le T, Lan KH, Chen Y, Kim K, Morris ZS. Tumor-Specific Antibody, Cetuximab, Enhances the In Situ Vaccine Effect of Radiation in Immunologically Cold Head and Neck Squamous Cell Carcinoma. Front Immunol 2020;11:591139. [PMID: 33281820 DOI: 10.3389/fimmu.2020.591139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
324 Forster MD, Dillon MT, Kocsis J, Remenár É, Pajkos G, Rolland F, Greenberg J, Harrington KJ. Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study. Eur J Cancer 2019;123:36-47. [PMID: 31648099 DOI: 10.1016/j.ejca.2019.08.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
325 Jaeger M, Nör C, de Farias CB, Abujamra AL, Schwartsmann G, Brunetto AL, Roesler R. Anti-EGFR therapy combined with neuromedin B receptor blockade induces the death of DAOY medulloblastoma cells. Childs Nerv Syst 2013;29:2145-50. [PMID: 24092425 DOI: 10.1007/s00381-013-2290-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
326 Ung N, Putoczki TL, Stylli SS, Ng I, Mariadason JM, Chan TA, Zhu HJ, Luwor RB. Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity. Cancer Biol Ther 2014;15:623-32. [PMID: 24556630 DOI: 10.4161/cbt.28179] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
327 Yang J, Li S, Wang B, Wu Y, Chen Z, Lv M, Lin Y, Yang J. Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer. Tumour Biol 2016;37:11645-55. [PMID: 27422777 DOI: 10.1007/s13277-016-5140-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
328 Silva ANS, Coffa J, Menon V, Hewitt LC, Das K, Miyagi Y, Bottomley D, Slaney H, Aoyama T, Mueller W, Arai T, Tan IB, Deng N, Chan XB, Tan P, Tsuburaya A, Sakamaki K, Hayden JD, Yoshikawa T, Zondervan I, Savola S, Grabsch HI. Frequent Coamplification of Receptor Tyrosine Kinase and Downstream Signaling Genes in Japanese Primary Gastric Cancer and Conversion in Matched Lymph Node Metastasis. Annals of Surgery 2018;267:114-21. [DOI: 10.1097/sla.0000000000002042] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
329 Patel GS, Karapetis CS. Personalized treatment for advanced colorectal cancer: KRAS and beyond. Cancer Manag Res. 2013;5:387-400. [PMID: 24294007 DOI: 10.2147/cmar.s35025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
330 Ross JS, Fakih M, Ali SM, Elvin JA, Schrock AB, Suh J, Vergilio JA, Ramkissoon S, Severson E, Daniel S, Fabrizio D, Frampton G, Sun J, Miller VA, Stephens PJ, Gay LM. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer. 2018;124:1358-1373. [PMID: 29338072 DOI: 10.1002/cncr.31125] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 14.5] [Reference Citation Analysis]
331 Hwang K, Yoon JH, Lee JH, Lee S. Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers. Biomedicines 2021;9:39. [PMID: 33466394 DOI: 10.3390/biomedicines9010039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
332 Yewale C, Baradia D, Vhora I, Patil S, Misra A. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials. 2013;34:8690-8707. [PMID: 23953842 DOI: 10.1016/j.biomaterials.2013.07.100] [Cited by in Crossref: 279] [Cited by in F6Publishing: 264] [Article Influence: 31.0] [Reference Citation Analysis]
333 Rubinson DA, Hochster HS, Ryan DP, Wolpin BM, McCleary NJ, Abrams TA, Chan JA, Iqbal S, Lenz HJ, Lim D. Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Invest New Drugs. 2014;32:113-122. [PMID: 23568716 DOI: 10.1007/s10637-013-9956-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
334 Li ZN, Zhao L, Yu LF, Wei MJ. BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. Gastroenterol Rep (Oxf) 2020;8:192-205. [PMID: 32665851 DOI: 10.1093/gastro/goaa022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
335 De Pauw I, Lardon F, Van den Bossche J, Baysal H, Pauwels P, Peeters M, Vermorken JB, Wouters A. Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib. Cancers (Basel) 2019;11:E98. [PMID: 30650638 DOI: 10.3390/cancers11010098] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
336 Afrăsânie VA, Marinca MV, Alexa-Stratulat T, Gafton B, Păduraru M, Adavidoaiei AM, Miron L, Rusu C. KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician. Radiol Oncol 2019;53:265-74. [PMID: 31553708 DOI: 10.2478/raon-2019-0033] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
337 Yeoh Y, Low TY, Abu N, Lee PY. Regulation of signal transduction pathways in colorectal cancer: implications for therapeutic resistance. PeerJ 2021;9:e12338. [PMID: 34733591 DOI: 10.7717/peerj.12338] [Reference Citation Analysis]
338 Wan ML, Wang Y, Zeng Z, Deng B, Zhu BS, Cao T, Li YK, Xiao J, Han Q, Wu Q. Colorectal cancer (CRC) as a multifactorial disease and its causal correlations with multiple signaling pathways. Biosci Rep. 2020;40. [PMID: 32149326 DOI: 10.1042/bsr20200265] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
339 Warren EAK, Anil J, Castro PD, Kemnade J, Suzuki M, Hegde M, Hicks J, Yu W, Sandulache V, Sikora AG. Human epidermal growth factor receptor 2 expression in head and neck squamous cell carcinoma: Variation within and across primary tumor sites, and implications for antigen-specific immunotherapy. Head Neck 2021;43:1983-94. [PMID: 33660372 DOI: 10.1002/hed.26662] [Reference Citation Analysis]
340 Yonesaka K, Tanaka K, Kitano M, Kawakami H, Hayashi H, Takeda M, Sakai K, Nishio K, Doi K, Nakagawa K. Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI. Oncogenesis 2019;8:54. [PMID: 31570699 DOI: 10.1038/s41389-019-0164-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
341 Zhuang QS, Sun XB, Chong QY, Banerjee A, Zhang M, Wu ZS, Zhu T, Pandey V, Lobie PE. ARTEMIN Promotes Oncogenicity and Resistance to 5-Fluorouracil in Colorectal Carcinoma by p44/42 MAPK Dependent Expression of CDH2. Front Oncol 2021;11:712348. [PMID: 34422665 DOI: 10.3389/fonc.2021.712348] [Reference Citation Analysis]
342 Chong CR, Jänne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19:1389-1400. [PMID: 24202392 DOI: 10.1038/nm.3388] [Cited by in Crossref: 580] [Cited by in F6Publishing: 550] [Article Influence: 64.4] [Reference Citation Analysis]
343 Wilkes EH, Casado P, Cutillas PR. Approaches for measuring signalling plasticity in the context of resistance to targeted cancer therapies. Biochem Soc Trans 2014;42:791-7. [PMID: 25109959 DOI: 10.1042/BST20140029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
344 Yonesaka K, Takegawa N, Watanabe S, Haratani K, Kawakami H, Sakai K, Chiba Y, Maeda N, Kagari T, Hirotani K, Nishio K, Nakagawa K. An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC. Oncogene 2019;38:1398-409. [PMID: 30302022 DOI: 10.1038/s41388-018-0517-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
345 Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17:33-48. [PMID: 31548601 DOI: 10.1038/s41571-019-0268-3] [Cited by in Crossref: 123] [Cited by in F6Publishing: 126] [Article Influence: 41.0] [Reference Citation Analysis]
346 Friedrich T, Leong S, Lieu CH. Beyond RAS and BRAF: a target rich disease that is ripe for picking. J Gastrointest Oncol 2016;7:705-12. [PMID: 27747084 DOI: 10.21037/jgo.2016.06.11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
347 Castoldi R, Schanzer J, Panke C, Jucknischke U, Neubert NJ, Croasdale R, Scheuer W, Auer J, Klein C, Niederfellner G, Kobold S, Sustmann C. TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations. Protein Eng Des Sel 2016;29:467-75. [PMID: 27578890 DOI: 10.1093/protein/gzw037] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
348 Patel B, Saba NF. Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck. Cancers (Basel) 2021;13:3545. [PMID: 34298761 DOI: 10.3390/cancers13143545] [Reference Citation Analysis]
349 Lee Y, Ma J, Lyu H, Huang J, Kim A, Liu B. Role of erbB3 receptors in cancer therapeutic resistance. Acta Biochim Biophys Sin (Shanghai) 2014;46:190-8. [PMID: 24449784 DOI: 10.1093/abbs/gmt150] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
350 Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016;8:57-84. [PMID: 26753006 DOI: 10.1177/1758834015614530] [Cited by in Crossref: 203] [Cited by in F6Publishing: 194] [Article Influence: 33.8] [Reference Citation Analysis]
351 Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Berns EM, Casado A, Lambrechts D, Jimeno A; European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG)., Groupe d’Investigateurs Nationaux pour les Etudes des Cancers de l’Ovaire (GINECO)., Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (A-AGO)., National Cancer Research Institute (NCRI)., Australia New Zealand Gynaecological Oncology Group (ANZGOG)., Mario Negri Gynecologic Oncology group (MaNGO). Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. Target Oncol 2015;10:583-96. [PMID: 26004768 DOI: 10.1007/s11523-015-0369-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
352 Morano F, Corallo S, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Murialdo R, Zaniboni A, Sartore-Bianchi A, Tomasello G, Racca P, Clavarezza M, Adamo V, Perrone F, Gloghini A, Tamborini E, Busico A, Martinetti A, Palermo F, Loupakis F, Milione M, Fucà G, Di Bartolomeo M, de Braud F, Pietrantonio F. Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. J Clin Oncol 2019;37:3099-110. [PMID: 31539295 DOI: 10.1200/JCO.19.01254] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 9.3] [Reference Citation Analysis]
353 Ni J, Zhang L. Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations. Onco Targets Ther 2021;14:4087-98. [PMID: 34262294 DOI: 10.2147/OTT.S312820] [Reference Citation Analysis]
354 Prenen H, Vecchione L, Van Cutsem E. Role of targeted agents in metastatic colorectal cancer. Targ Oncol 2013;8:83-96. [DOI: 10.1007/s11523-013-0281-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
355 Taniguchi F, Nyuya A, Toshima T, Yasui K, Mori Y, Okawaki M, Kishimoto H, Umeda Y, Fujiwara T, Tanioka H, Yamaguchi Y, Goel A, Nagasaka T. Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer. Future Sci OA 2021;7:FSO757. [PMID: 34840814 DOI: 10.2144/fsoa-2021-0059] [Reference Citation Analysis]
356 Cremolini C, Morano F, Moretto R, Berenato R, Tamborini E, Perrone F, Rossini D, Gloghini A, Busico A, Zucchelli G, Baratelli C, Tamburini E, Tampellini M, Sensi E, Fucà G, Volpi C, Milione M, Di Maio M, Fontanini G, De Braud F, Falcone A, Pietrantonio F. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. Ann Oncol 2017;28:3009-14. [PMID: 29045518 DOI: 10.1093/annonc/mdx546] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 11.0] [Reference Citation Analysis]
357 Yonesaka K, Hirotani K, Kawakami H, Takeda M, Kaneda H, Sakai K, Okamoto I, Nishio K, Jänne PA, Nakagawa K. Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib. Oncogene 2016;35:878-86. [PMID: 25961915 DOI: 10.1038/onc.2015.142] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 7.1] [Reference Citation Analysis]
358 Parseghian CM, Napolitano S, Loree JM, Kopetz S. Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. Clin Cancer Res 2019;25:6899-908. [PMID: 31263029 DOI: 10.1158/1078-0432.CCR-19-0823] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 8.7] [Reference Citation Analysis]
359 Amin AD, Rajan SS, Liang WS, Pongtornpipat P, Groysman MJ, Tapia EO, Peters TL, Cuyugan L, Adkins J, Rimsza LM. Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors. Cancer Res. 2015;75:2916-2927. [PMID: 26018086 DOI: 10.1158/0008-5472.can-14-3437] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
360 Hartmann S, Brands RC, Küchler N, Fuchs A, Linz C, Kübler AC, Müller-Richter UD. Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer. Oncol Lett 2015;10:1211-7. [PMID: 26622654 DOI: 10.3892/ol.2015.3345] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
361 Foubert F, Matysiak-budnik T, Touchefeu Y. Options for metastatic colorectal cancer beyond the second line of treatment. Digestive and Liver Disease 2014;46:105-12. [DOI: 10.1016/j.dld.2013.07.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
362 Okamoto I, Nakagawa K. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects. Cancer Sci 2012;103:1391-6. [PMID: 22568572 DOI: 10.1111/j.1349-7006.2012.02327.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
363 Pandey JP. Mechanism of resistance to cetuximab therapy in colorectal cancer: Possible role of antibodies to immunoglobulin allotypes. MAbs 2012;4:553-4. [PMID: 22820100 DOI: 10.4161/mabs.21311] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
364 Nam SK, Yun S, Koh J, Kwak Y, Seo AN, Park KU, Kim DW, Kang SB, Kim WH, Lee HS. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis. PLoS One. 2016;11:e0151865. [PMID: 26991109 DOI: 10.1371/journal.pone.0151865] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
365 Martinelli E, Troiani T, Sforza V, Martini G, Cardone C, Vitiello PP, Ciardiello D, Rachiglio AM, Normanno N, Sartore-Bianchi A, Marsoni S, Bardelli A, Siena S, Ciardiello F. Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. ESMO Open. 2018;3:e000299. [PMID: 29387480 DOI: 10.1136/esmoopen-2017-000299] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
366 Laurent-Puig P, Manceau G, Zucman-Rossi J, Blons H. Dual blockade of epidermal growth factor receptor-induced pathways: a new avenue to treat metastatic colorectal cancer. J Clin Oncol 2012;30:1550-2. [PMID: 22412137 DOI: 10.1200/JCO.2011.40.1190] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
367 Forest A, Amatulli M, Ludwig DL, Damoci CB, Wang Y, Burns CA, Donoho GP, Zanella N, Fiebig HH, Prewett MC, Surguladze D, DeLigio JT, Houghton PJ, Smith MA, Novosiadly R. Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor. Mol Cancer Res 2015;13:1615-26. [PMID: 26263910 DOI: 10.1158/1541-7786.MCR-15-0279] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
368 Iida M, Bahrar H, Brand TM, Pearson HE, Coan JP, Orbuch RA, Flanigan BG, Swick AD, Prabakaran PJ, Lantto J, Horak ID, Kragh M, Salgia R, Kimple RJ, Wheeler DL. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. Mol Cancer Ther 2016;15:2175-86. [PMID: 27422810 DOI: 10.1158/1535-7163.MCT-16-0012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
369 Spiliopoulou P, Arkenau HT. Rationally designed treatment for metastatic colorectal cancer: Current drug development strategies. World J Gastroenterol 2014; 20(30): 10288-10295 [PMID: 25132745 DOI: 10.3748/wjg.v20.i30.10288] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
370 Lupo B, Sassi F, Pinnelli M, Galimi F, Zanella ER, Vurchio V, Migliardi G, Gagliardi PA, Puliafito A, Manganaro D, Luraghi P, Kragh M, Pedersen MW, Horak ID, Boccaccio C, Medico E, Primo L, Nichol D, Spiteri I, Heide T, Vatsiou A, Graham TA, Élez E, Argiles G, Nuciforo P, Sottoriva A, Dienstmann R, Pasini D, Grassi E, Isella C, Bertotti A, Trusolino L. Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype. Sci Transl Med 2020;12:eaax8313. [PMID: 32759276 DOI: 10.1126/scitranslmed.aax8313] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
371 Guo S, Chen D, Huang X, Cai J, Wery JP, Li QX. Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature. Oncotarget 2016;7:50575-81. [PMID: 27409671 DOI: 10.18632/oncotarget.10499] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
372 Shan L, Lv Y, Bai B, Huang X, Zhu H. Variability in HER2 expression between primary colorectal cancer and corresponding metastases. J Cancer Res Clin Oncol 2018;144:2275-81. [PMID: 30203148 DOI: 10.1007/s00432-018-2744-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
373 Filip S, Vymetalkova V, Petera J, Vodickova L, Kubecek O, John S, Cecka F, Krupova M, Manethova M, Cervena K, Vodicka P. Distant Metastasis in Colorectal Cancer Patients-Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review. Int J Mol Sci 2020;21:E5255. [PMID: 32722130 DOI: 10.3390/ijms21155255] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
374 Troiani T, Napolitano S, Della Corte CM, Martini G, Martinelli E, Morgillo F, Ciardiello F. Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. ESMO Open 2016;1:e000088. [PMID: 27843640 DOI: 10.1136/esmoopen-2016-000088] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 9.3] [Reference Citation Analysis]
375 Pollock NI, Wang L, Wallweber G, Gooding WE, Huang W, Chenna A, Winslow J, Sen M, DeGrave KA, Li H, Zeng Y, Grandis JR. Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies. Clin Cancer Res 2015;21:4597-606. [PMID: 26138066 DOI: 10.1158/1078-0432.CCR-14-3338] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
376 Schmitz S, Ang KK, Vermorken J, Haddad R, Suarez C, Wolf GT, Hamoir M, Machiels JP. Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions. Cancer Treat Rev 2014;40:390-404. [PMID: 24176789 DOI: 10.1016/j.ctrv.2013.09.007] [Cited by in Crossref: 62] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
377 Chowdhury SM, Xie S, Fang J, Lee SK, Sitharaman B. Nanoparticle-Facilitated Membrane Depolarization-Induced Receptor Activation: Implications on Cellular Uptake and Drug Delivery. ACS Biomater Sci Eng 2016;2:2153-61. [PMID: 33465891 DOI: 10.1021/acsbiomaterials.6b00338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
378 Napolitano S, Martini G, Martinelli E, Belli V, Parascandolo A, Laukkanen MO, Sforza V, Morgillo F, Ciardiello D, Ciardiello F, Troiani T. Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. Oncotarget 2017;8:67592-604. [PMID: 28978055 DOI: 10.18632/oncotarget.18749] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
379 Gracia-Cazaña T, Salazar N, Zamarrón A, Mascaraque M, Lucena SR, Juarranz Á. Resistance of Nonmelanoma Skin Cancer to Nonsurgical Treatments. Part II: Photodynamic Therapy, Vismodegib, Cetuximab, Intralesional Methotrexate, and Radiotherapy. Actas Dermosifiliogr 2016;107:740-50. [PMID: 27436804 DOI: 10.1016/j.ad.2016.04.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]